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Introduction
Skin development is a complex dynamic process that results 
in formation of the epidermis, a stratified self-renewed epi-
thelium, and several skin appendages including hair follicles 
(HFs), nails, and glands (Blanpain and Fuchs, 2009). HF mor-
phogenesis is driven by bidirectional ectodermal–mesenchymal 
interactions between epidermal keratinocytes and a specialized 
population of dermal fibroblasts, and results in formation of the 
hair bulb, in which epithelial progenitor cells proliferate and 
differentiate into six distinct cell lineages to form the hair shaft 
and its supporting layers of the inner root sheath (Millar, 2002; 
Schmidt-Ullrich and Paus, 2005; Blanpain and Fuchs, 2009). 
HF morphogenesis is governed by a well-balanced interplay 
between cell proliferation, differentiation, and apoptosis, which 
are controlled at several levels including signaling/transcription 
factor-mediated and epigenetic regulatory mechanisms (Millar, 
2002; Schmidt-Ullrich and Paus, 2005; Blanpain and Fuchs, 
2009; Botchkarev et al., 2012; Frye and Benitah, 2012).
During postnatal life, HFs undergo cyclic regeneration 
with periods of active growth (anagen), regression (catagen), 
and relative resting (telogen; Stenn and Paus, 2001; Schneider 
et al., 2009). Initiation of a new growth phase in resting HFs 
occurs as a result of signaling exchange between epithelial 
stem cells residing in the bulge/secondary hair germ and der-
mal papilla fibroblasts, and is driven by the growth stimulatory 
molecules (Wnt ligands, BMP inhibitors, Shh, TGF-2, FGF7, 
FGF10), the effects of which predominate over the growth in-
hibitory signals generated by the BMP ligands or FGF18 (Hsu 
and Fuchs, 2012).
In addition to signaling/transcription factor–mediated and 
epigenetic regulatory mechanisms, programs of gene activation 
and silencing governing HF development and cycling are controlled 
by microRNAs (miRNAs; Yi and Fuchs, 2011; Botchkareva, 
Skin development is governed by complex pro-grams of gene activation and silencing, includ-ing microRNA-dependent modulation of gene 
expression. Here, we show that miR-214 regulates skin 
morphogenesis and hair follicle (HF) cycling by target-
ing -catenin, a key component of the Wnt signaling 
pathway. miR-214 exhibits differential expression pat-
terns in the skin epithelium, and its inducible overex-
pression in keratinocytes inhibited proliferation, which 
resulted in formation of fewer HFs with decreased hair 
bulb size and thinner hair production. The inhibitory 
effects of miR-214 on HF development and cycling were 
associated with altered activities of multiple signaling 
pathways, including decreased expression of key Wnt 
signaling mediators -catenin and Lef-1, and were res-
cued by treatment with pharmacological Wnt activators. 
Finally, we identify -catenin as one of the conserved 
miR-214 targets in keratinocytes. These data provide an 
important foundation for further analyses of miR-214 as 
a key regulator of Wnt pathway activity and stem cell 
functions during normal tissue homeostasis, regenera-
tion, and aging.
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Figure 1. Spatiotemporal expression of miR-214 during HF morphogenesis and cycling. (A–C) TaqMan real-time RT-PCR analysis of miR-214 expression. 
(A) miR-214 levels in in the skin of newborn mice at P0.5 compared with embryonic skin at E14.5. n = 3 mice for each time point. Data are presented 
as mean ± SD (error bars); **, P < 0.01; Student’s t test. (B) miR-214 levels in skin during the postnatal hair cycle: anagen-like stage (P12), catagen 
(P16–P17), and telogen (P20–P22). n = 2 mice for each time point. Data are presented as mean ± SEM (error bars). (C) miR-214 in depilation-induced 
hair cycle: telogen (day 0), anagen (days 3–12), and catagen (days 17–19). n = 2 mice for each time point. Data are presented as mean ± SEM (error 
bars). (D–G) miR-214 in situ hybridization. (D) miR-214 in the developing epidermis using Tyramide Signal Amplification for fluorescent detection. miR-
214 expression was detected in the suprabasal epidermal layers at E14.5 (arrow); more prominent miR-214 signal is visible throughout the epidermis 
at E17.5 and P3.5 (arrows). The broken lines demarcate the epidermal–dermal border. (E) HF morphogenesis. miR-214 appears in the developing hair 
placodes at E17.5 (arrow). At P0.5, miR-214 is expressed throughout the epithelium of stage 3–6 HFs (arrow). In fully developed HFs (stage 8, P3.5), 
miR-214 expression increased in the developing hair matrix (arrow) and individual cells of the outer root sheath (arrowheads). (F) Hair cycle. miR-214 is 
expressed in telogen secondary germ (arrow), and appears in the hair matrix (arrow), outer root sheath (small arrow), and in the bulge area (arrowheads) 
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in mid-anagen HF. In late anagen, prominent expression of miR-214 in the hair matrix (arrows) and in the outer root sheath (arrowheads) is seen. In 
catagen, miR-214 is expressed in the regressing hair matrix (arrow), outer root sheath (small arrow), and in the epithelial strand of the mid-catagen HF 
(arrowheads), whereas it disappears from the epithelial strand in the advanced catagen HFs (asterisk). (G) The scramble negative control using Tyramide 
(left) and chromogenic (right) detections. The broken line demarcates the epidermal–dermal border. Bars: (D) 25 µm; (E, left two panels) 25 µm; (E, right) 
50 µm; (F) 50 µm; (G) 25 µm.
 
2012; Ning and Andl, 2013). miRNAs largely contribute to the 
regulation of gene expression by fine tuning and buffering the 
activity of signaling pathways. miRNAs interact with their 
target complimentary messenger RNAs by base-pairing be-
tween 5 end sequences of miRNAs and mRNAs sequences 
located in the 3 untranslated region (3 UTR), which leads to 
either mRNA destabilization, the inhibition of translation ini-
tiation, or both (Lee et al., 1993; Ambros, 2001). In turn, the 
expression of miRNA can be controlled by cell type–specific 
transcription factors, and a major constituent of the miRNA 
processing machinery, Dicer, serves as a target gene of p63 and 
microphthalmia-associated transcription factor (MITF) in epi-
thelial cells and melanocytes, respectively (Levy et al., 2010; 
Su et al., 2010). In addition, miRNAs can alter activities of the 
signaling pathways not only by targeting their genes, but also by 
acting as their downstream components (Ahmed et al., 2011). 
Therefore, miRNAs and their targets represent remarkably di-
verse regulatory networks, playing a key role in the execution 
of gene expression programs in stem cells and their progenies 
(Ambros, 2001; Inui et al., 2010).
Recent data demonstrated critical roles of miRNAs in 
controlling the activity of cutaneous stem cells and their lineage-
committed progenies that drive skin development and regenera-
tion (Yi and Fuchs, 2011; Botchkareva, 2012; Ning and Andl, 
2013). Early studies by Andl et al. (2006) and Yi et al. (2006) 
have identified 70 miRNAs expressed in mouse embryonic 
skin. We have recently shown that expression levels of >200 
miRNAs are changed during HF cyclic regeneration in mouse 
skin (Mardaryev et al., 2010). These findings suggest that mi-
RNAs play a powerful role in the control of gene expression pro-
grams during skin development and hair cycle–associated tissue 
remodeling. Indeed, constitutive epidermal-specific deletion of 
the miRNA processors Dicer or Dgcr8 results in the severe abnor-
malities in HF development characterized by the inability of 
the HFs to invaginate into the dermis (Andl et al., 2006; Yi 
et al., 2006). Inducible epidermal deletion of Dicer or Drosha in 
postnatal mouse skin has also demonstrated the crucial impor-
tance of miRNAs in the maintenance of the normal HF growth 
cycle (Teta et al., 2012).
Individual miRNAs are involved in controlling the ex-
pression of several key regulators of stem cell activity in the 
skin and HFs: miR-203 controls the proliferative potential of 
epithelial precursor cells by direct inhibition of p63 expression 
(Lena et al., 2008; Yi et al., 2008), and miR-125b serves as a 
rheostat that controls stem cell proliferation, fate commitment, 
and differentiation (Zhang et al., 2011), while miR-205 is indis-
pensable for stem cell survival (Wang et al., 2013a). miR-31 is 
highly expressed in the HF during the anagen phase and con-
trols hair cycle–associated tissue remodeling by regulating the 
expression of several important components of the Wnt, BMP, 
and FGF signaling pathways (Mardaryev et al., 2010).
Although substantial progress has been made in discover-
ing the important players controlling skin and HF development 
and cycling, understanding the molecular mechanisms involved 
in the establishment of signaling/transcription networks in the 
keratinocytes still requires additional efforts. In this study, we 
aimed to explore a role of miR-214 in HF development and cy-
cling. Yi et al. (2006) showed that miR-214 is one of the most 
abundant miRNAs expressed in the HFs of embryonic day 17.5 
(E17.5) embryonic skin. Mouse miR-214 is encoded by a pri-
mary transcript Dynamin3-opposite strand (Dnm3os; Liu et al., 
2010), deletion of which leads to skeletal abnormalities and a 
lethal phenotype (Watanabe et al., 2008). The expression of the 
miR-214 gene is developmentally regulated by Twist-1, a key 
transcriptional factor controlling epithelial–mesenchymal tran-
sitions (Lee et al., 2009), which is crucial for normal develop-
ment and tissue repair. It has also been demonstrated that 
miR-214 plays an important role in controlling the development 
of the nervous system, teeth, the pancreas, and bone formation 
(Joglekar et al., 2007; Chen et al., 2010; Sehic et al., 2011; 
Wang et al., 2013b). However, its role in the control of skin and 
HF development and homeostasis is unknown.
In this study, we demonstrate that miR-214 show dis-
tinct expression patterns in the developing epidermis and HF. 
Keratinocyte-specific miR-214 overexpression causes a marked 
decrease in the number of HFs in developing skin, and a delay 
in anagen progression during postnatal development, which is 
associated with inhibition of cell proliferation in the epidermis 
and HFs. These effects are accompanied by dramatic changes 
in the gene expression and activity of different signaling path-
ways including Wnt, Shh, Eda, and Bmp, and are rescued by 
the administration of Wnt pathway activators. Furthermore, we 
identified -catenin as a direct miR-214 target, which suggests 
that miR-214 is an important regulator of Wnt signaling path-
way activity in developing and postnatal skin.
Results
miR-214 exhibits distinct expression 
patterns in the epidermis and HFs in 
developing and postnatal skin
To understand the role of miR-214 in the control of skin mor-
phogenesis and HF cycling, miR-214 expression was examined 
in mouse back skin at different developmental stages, as well as 
during the first postnatal and depilation-induced hair cycles. Low 
levels of miR-214 expression were detected in embryonic skin 
at E14.5 during onset of the HF development, while its expres-
sion was dramatically elevated in the total skin of newborn mice 
containing HFs at different stages of development (Fig. 1 A). 
High miR-214 expression levels were maintained in the skin 
until P12, while its expression was decreased significantly dur-
ing HF transition to the first regressing phase (catagen, P16-17) 
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Figure 2. Inhibitory effects of miR-214 on skin and HF morphogenesis. (A) Schematic representation of the constructs for generation of K14-rtTA/miR-214-
TRE (DTG) mice. (B) Real-time RT-PCR. There were increased levels of miR-214 in the skin of neonatal DTG mice at P0. n = 3 mice/genotype. (C) mCherry 
fluorescence in the epithelium of DTG mice at E15.5 after activation by Dox after E10.5. The broken lines demarcate the epidermal–dermal border. 
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(D) DTG and WT littermates were given Dox after E10.5 and photographed at P15. (E) Immunofluorescence of Ki-67 (red) in the epidermis of E15 skin with 
nuclear staining (DAPI, blue). There was a significant decrease of Ki-67+ cells at E15 and P8.5 in DTG epidermis. n = 3 mice/genotype for each time point. 
(F) Decrease in the epidermal thickness in DTG mice at E15, P0.5, and P8.5. n = 3 mice/genotype for each time point. (G) Immunofluorescence of BrdU 
(red) and K14 (green) in the epidermis of P6 skin with nuclear staining (DAPI, blue). There was a significant reduction in BrdU+ cells in both basal and 
suprabasal epidermal layers of DTG versus WT mice. n = 3 mice/genotype for each time point. (H) Immunofluorescence of K14 (red), K10 (green), and 
Loricrin (green) in the E15.5 epidermis and Loricrin (red) in the P6.5 epidermis with nuclear staining (DAPI, blue). There were no differences in the expres-
sion of K14, K10, and Loricirin between DTG and WT in E15 skin. There was increased Loricrin expression in DTG epidermis at P6.5. (I) Representative 
microphotographs of back skin histology of DTG and WT mice at different embryonic and postnatal days of skin and HF development. Arrows indicate HF 
placodes, and the broken lines demarcate the epidermal–dermal border. (J) Quantification of the total HF number per millimeter of skin in DTG versus WT 
littermate at E15, E17, P0.5, and P8.5. n = 3 mice/genotype for each time point. (K) Immunodetection of pH3(Ser28) (red) with nuclear staining (DAPI, 
blue) in the hair bulbs of DTG and WT mice at P8.5. (L) Quantification of a ratio of pH3(Ser28)+ to total cell number in the hair matrix at P8.5. n = 3 
mice/genotype. (M) Significant reduction in hair bulb diameter in the DTG HFs at P8. n = 3 mice/genotype. (N) Quantification of the number of dermal 
papilla cells at P8.5. n = 3 mice/genotype. (O) Representative images of the different hair shaft types (guard, awl, auchene, and zigzag) plucked from 
telogen HFs of DTG and WT mice at P20. G, guard; Aw, awl; Ach, auchene; Z, zigzag. (P) Quantification of the number of different hair shaft types in 
DTG and WT mice. No difference between DTG and WT mice was detected. n = 4 mice/genotype. (Q) Significant decrease in the hair shaft thickness of 
the awl, auchene, and zigzag hairs in DTG versus WT mice. n = 4 mice/genotype. Data are presented as mean ± SD (error bars); *, P < 0.05; **, P < 
0.01; ***, P < 0.001; Student’s t test. Bars: (C, E, I, K, and O) 50 µm; (G and H) 25 µm.
 
and remained low during subsequent resting phase (telogen; 
P20-22; Fig. 1 B). Similar fluctuations in the miR-214 levels were 
observed in adult skin during depilation-induced hair cycle: 
miR-214 expression progressively increased during HF transi-
tion from telogen to anagen and was maximal during the late 
anagen stage of the hair cycle (day 12 after depilation) followed 
by rapid decrease during catagen (Fig. 1 C).
In situ hybridization analysis showed that in E14.5 and 
E17.5 skin, miR-214 expression was seen in the suprabasal epi-
dermal layers, whereas in postnatal day 3.5 (P3.5) skin, rela-
tively weak miR-214 expression was also seen in the basal 
epidermal layer (Fig. 1 D). miR-214 was abundantly expressed 
throughout the epithelium in the HF placodes and during more 
advanced stages of HF morphogenesis (E17.5–P0.5; Fig. 1 E; 
see Fig. 7 E). In fully developed HFs, miR-214 expression sub-
stantially increased in the developing hair matrix and individual 
cells of the outer root sheath (P3.5; Fig. 1 E).
During HF cycling, miR-214 expression was restricted to 
the secondary germ of the telogen HFs, while in early anagen 
HFs, miR-214 expression appeared in the growing hair matrix, 
the outer root sheath, and in the bulge area (Fig. 1 F). In fully 
developed anagen HFs, miR-214 was prominently expressed in 
the hair matrix, as well as in the distinct cells of the outer root 
sheath (Fig. 1 F; see Fig. 7 E). During catagen, miR-214 expres-
sion was seen in the regressing hair matrix, outer root sheath, 
and in the epithelial strand of the mid-catagen HF, whereas 
its expression disappeared from the epithelial strand at the ad-
vanced catagen stages (Fig. 1 F). These data suggest that miR-214 
exhibits discrete expression patterns in selected epithelial com-
partments of the skin: it is predominantly localized in the supra-
basal epidermal layers and in the epithelium of the developing 
HFs, as well as in the secondary germ of telogen HFs and hair 
matrix of anagen HFs.
Krt14-driven miR-214 overexpression 
results in alterations of epidermal and  
HF development
To amplify the miR-214 effects on the epithelial progenitor cell 
population located in the basal epidermal layer and HF outer 
root sheath, where miR-214 was relatively underexpressed 
compared with more the differentiated keratinocytes of the su-
prabasal epidermal layer and HF matrix keratinocytes (Fig. 1, 
D–F), mice overexpressing miR-214 under the control of doxy-
cycline (Dox)-inducible Krt14-promoter (K14-rtTA/miR-214-
TRE double transgenic [DTG]) were generated (Fig. 2 A). 
Induction of transgene by Dox starting from E10.5, which cor-
responds to the onset of Krt14 expression in the developing epi-
dermis (Byrne et al., 1994), caused a dramatic increase in the 
level of miR-214 in the skin of DTG mice. This was confirmed 
by RT-qPCR (Fig. 2 B). Transgene expression was also con-
firmed by mCherry fluorescence in the basal epidermal layer of 
E15.5 skin (Fig. 2 C).
DTG mice were viable, fertile, and showed appearance of 
a “rough” fur coat postnatally (Fig. 2 D).
Between E15.5 and P8.5, DTG mice showed significantly 
decreased epidermal proliferation and thinner epidermis com-
pared with wild type (WT) controls (Fig. 2, E and F). When P6 
DTG and WT mice were pulsed with BrdU for 12 h followed by 
the costaining of BrdU and either K14 or K10, the majority of 
BrdU-positive cells were seen in the basal K14+ cells in both 
DTG and WT mice. However, it was a significant reduction in 
the number of BrdU+ cells in both basal and suprabasal epider-
mal layers of DTG mice compared with WT control (Fig. 2 G).
The expression of Keratin 14, Keratin 10, and Loricrin 
in basal or suprabasal epidermal layers, respectively, was quite 
similar in E15.5 DTG mice compared with WT mice (Fig. 2 H). 
However, Dox-treated epidermis of newborn DTG mice exhib-
ited the increase of Lor transcript compared with the control 
(Fig. S1 A). Also, increased Loricrin protein expression was 
seen in the upper layers of the epidermis of the P6.5 DTG mice 
versus age-matched WT mice (Fig. 2 H). Therefore, decreased 
epidermal thickness in miR-214 DTG mice could be developed 
because of the reduced keratinocyte proliferation and acceler-
ated terminal differentiation in the epidermis.
Interestingly, miR-214 overexpression caused a lack of 
30% of HFs in the back skin (Fig. 2, I and J). The number of 
induced HFs was significantly decreased in DTG mice at E15.5, 
E17.5, P0.5, and P8.5 compared with WT controls (Fig. 2, 
I and J), which suggests that miR-214 overexpression alters 
the induction process in both primary and secondary HFs. The 
rate of HF development was not significantly different between 
DTG and WT mice; all HFs in DTG and WT mice reached the 
first anagen phase at P8.5 (Fig. 2 I). However, all transgenic 
HFs at P8.5 showed significantly reduced length, which was 
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Figure 3. Gain of miR-214 function inhibits hair cycle progression. (A) Schematic illustration of the experimental design. (B) Representative microphoto-
graphs of back skin histology of DTG and WT mice at different days of a depilation-induced hair cycle. Bars, 50 µm. (C) Quantitative histomorphometry of 
HFs at different anagen substages at days 3 and 5 after depilation in DTG and WT mice. n = 5 mice/genotype for each time point. (D) Quantification of HF 
length at days 5 and 12 after depilation. n = 5 mice/genotype for each time point. (E) Quantification of hair bulb diameter in the HFs at day 5 and 12 after 
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depilation. n = 5 mice/genotype for each time point. (F) Immunodetection of pH3(Ser28) (red) in the hair bulbs of DTG and WT mice with nuclear stain-
ing (DAPI, blue). A significant reduction in the number of pH3(Ser28)+ cells in the HF of DTG mice at days 3, 5, and 12 after depilation was seen. n = 5 
mice/genotype for each time point. Bar, 50 µm. (G) Real-time RT-PCR analysis of Cdkn2a and Cdkn2d expression at day 12 after depilation. n = 3 mice/
genotype. (H) Quantification of the number of dermal papilla cells in anagen HFs at day 12 after depilation. n = 5 mice/genotype for each time point. 
(I) Quantification of the hair shaft thickness of the awl, auchene, and zigzag hairs in DTG versus WT mice plucked after the hair cycle completion at day 
20 after depilation. n = 5 mice/genotype. Data are presented as mean ± SD (error bars); *, P < 0.05; **, P < 0.01; ***, P < 0.001; Student’s t test.
 
accompanied by markedly reduced total skin thickness (Fig. S1, 
B and C). The hair bulb size and cell proliferation in the HF ma-
trix were significantly reduced in all HFs of DTG mice versus 
the WT HFs (Fig. 2, I and K–M), whereas no apoptotic cells 
were detected in the HFs or interfollicular epidermis in DTG or 
WT mice (not depicted). In addition, a significant decrease in 
the number of dermal papilla cells was observed in transgenic 
HFs versus the corresponding controls (Fig. 2 N).
Despite the fact that the proportions of the guard, awl, 
auchen, and zigzag hair in DTG mice were similar to WT mice 
(Fig. 2, O and P), morphometric analyses of their hair shafts 
(P20; telogen HFs) revealed a significant decrease of their thick-
ness but not the length in DTG versus WT mice (Fig. 2 Q and 
Fig. S1 D). Therefore, the changes in visual coat appearance in 
DTG mice were most likely caused by the reduced number of 
the HFs, as well as by the decreased thickness of the hair shafts 
induced by miR-214 overexpression.
Gain of miR-214 activity in postnatal skin 
alters HF cycling and HF size
To explore the effects of miR-214 on HF cycling, DTG mice 
were treated with Dox during telogen phase followed by the 
induction of the hair cycle by depilation (Fig. 3 A). Although 
telogen–anagen transition was initiated in DTG mice, they ex-
hibited a significant delay in early anagen development com-
pared with WT control (days 3 and 5 after depilation; Fig. 3, 
B and C). Anagen VI HFs were significantly shorter in DTG 
mice compared with WT mice (Fig. 3 D). On days 5–12 after 
depilation, the size of hair bulbs in DTG HFs was significantly 
reduced compared with WT controls (Fig. 3 E). These changes 
were associated with significantly decreased cell proliferation 
in the hair matrix and increased transcript levels of the cyclin-
dependent kinase inhibitors Cdkn2a (p16) and Cdkn2d (p19) in 
DTG skin compared with WT mice (Fig. 3, F and G). Analysis 
of apoptosis by the detection of active caspase-3 did not reveal 
any differences between HFs in DTG and WT mice (Fig. S1 E). 
The number of dermal papilla cells in transgenic anagen VI HFs 
was significantly reduced (Fig. 3 H). Similar to HF morpho-
genesis, anagen DTG HFs produced significantly thinner hair 
shafts compared with WT controls (Fig. 3 I). These data suggest 
that miR-214 exerts its effects on HF development and cycling 
by modulation of keratinocyte proliferation and differentiation, 
as well as by regulating epithelial–mesenchymal interactions in 
the HF including the control of dermal papilla cell number.
miR-214 overexpression induces complex 
changes in gene expression programs in 
keratinocytes
To explore molecular mechanisms underlying the phenotype 
in miR-214 transgenic mice and identify potential targets of 
miR-214 in the keratinocytes, global mRNA expression profil-
ing was performed in the back skin epithelium of neonatal DTG 
mice (P2.5), which received Dox for 48 h before skin collection 
(Fig. 4 A). The raw microarray expression profiles were back-
ground corrected and normalized with Bioconductor package 
limma (Smyth, 2005), and genes with more than twofold ex-
pression change in the epithelium of DTG mice compared with 
WT controls were identified as differentially expressed (Fig. 4 B). 
The in-house functional ontology database was used to cate-
gorize differentially expressed genes into the set of 12 distinct 
functional categories (Lewis et al., 2014). Bioinformatic analysis 
revealed twofold and higher changes in expression of 1,026 
genes in skin epithelium of DTG versus WT mice (Fig. 4 B and 
Tables S1 and S2). Differentially expressed genes that belong 
to the “cell cycle” and “signaling” categories were further vali-
dated by RT-qPCR.
Using RT-qPCR, we confirmed that the transcript levels 
of Ccnb1, Ccnd1, Ccnd2, and Cdk1 (cyclin B1, cyclin D1, 
cyclin D2, and cyclin-dependent kinase 1) were significantly 
lower in DTG mice compared with the WT littermates (Fig. 4 C). 
These data suggest that miR-214 indeed exerts inhibitory effects 
on cell proliferation, which were consistent with the epidermal 
and HF phenotypes seen in DTG mice (Figs. 2 and 3).
Interestingly, microarray analysis revealed changes in the 
expression of the genes encoding the components of several 
signaling pathways that are crucial for HF development and cy-
cling, such as Wnt, Shh, Edar, and Bmp (Botchkarev and Paus, 
2003; Schmidt-Ullrich et al., 2006; Blanpain and Fuchs, 2009). 
RT-qPCR confirmed significant down-regulation of the Ctnnb1 
and Lef-1 expressions in the skin of DTG mice, which suggests 
inhibition of Wnt signaling activity induced by miR-214. Also, 
expressions of several genes that belong to Hedgehog signaling, 
such as Shh and its receptors Smo and Ptch2, were dramatically 
decreased in the epithelium of DTG versus WT mice. In addi-
tion, overexpression of miR-214 led to a significant decrease in 
the expression of Edar and the BMP inhibitor Sostdc1 (Fig. 4 C). 
These data provide evidence that the effects of miR-214 on 
HF development and cycling are mediated, at least in part, by 
genes that control keratinocyte proliferation and mediate activ-
ity of key signaling pathways (Wnt, Hedgehog, Bmp, and Edar) 
known to be crucial for skin development and hair growth.
miR-214 overexpression in epithelial 
progenitor cells alters expression of key 
regulators of HF development and cycling
To further investigate the effects of gain of miR-214 functions 
on the activity of selected signaling pathways in skin, we ana-
lyzed the pattern of the expression of their different components 
in embryonic and postnatal skin of DTG and age-matched WT 
mice. Quantitative immunofluorescence analysis revealed the 
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(Fig. S1 G). However, there were no changes in the expression of 
selected stem cell markers, such as Sox9 and Lhx2, between the 
hair placodes of DTG and WT mice (Fig. S1 H).
Similar to the HF development, elevation of miR-214 
levels during hair cycle resulted in decreased expressions of 
-catenin and Lef-1 in the hair matrix and the dermal papilla 
of DTG follicles, whereas Sox2 expression in the dermal pa-
pilla remained unchanged (Fig. 6, A, B, and G; and Fig. S1 I).[ID]FIG6[/ID] 
Also, quantitative immunofluorescence analysis revealed in-
creased expression of pSmad 1/5/8 in differentiating HF ke-
ratinocytes of DTG versus WT mice (Fig. 6, C and G). Shh 
expression was strongly decreased in the hair matrix of DTG 
HFs (Fig. 6, D and G). Consistent with microarray data, ex-
pression of cyclin D1 was also decreased in the hair matrix of 
DTG HFs (Fig. 6, E and G), and reduced expression of cyclin-
dependent kinase 1 was also seen in the hair matrix of miR-214 
transgenic mice (Fig. 6, F and G). In addition, expression of the 
decreased levels of -catenin, the downstream component of 
the Wnt pathway, in the HF placode epithelium of DTG mice 
(stages 1–2 of HF development; Fig. 5, A and H).[ID]FIG5[/ID] Consistent with 
these data, a significant decrease of the -catenin protein levels 
in the total skin of DTG mice was confirmed by Western blotting 
(Fig. 5 A). Lef-1 expression was also markedly decreased in 
the HF placode epithelium and in the developing dermal papilla 
(Fig. 5, B and H). In contrast, pSmad1/5/8 expression increased 
in the developing hair placodes and interfollicular epidermis of 
DTG mice versus WT controls, which suggests activation of BMP 
signaling driven by miR-214 overexpression (Fig. 5, C and H). 
Gain of miR-214 in the skin also resulted in the reduced expres-
sion of Shh (Fig. 5, D and I; and Fig. S1 F) and Edar (Fig. 5, D, 
E, and H). Analysis of Cyclin D1 and Cyclin D2 expression 
also revealed their decreased expression in the developing hair 
placodes (Fig. 5, F–H), as well as a reduced number of Cyclin 
D1–positive cells in the epidermis of DTG mice versus WT mice 
Figure 4. Global gene expression profiling of the back skin epithelium of WT and K14-rtTA/miR-214-TRE mice. (A) Schematic illustration of the experimen-
tal design. (B) Agilent microarray analysis of the back skin epithelium of DTG and WT mice. A bar chart depicts the ontology of the down- and up-regulated 
genes and the actual number of genes with more than twofold expression change in DTG and WT skin; (a full list of the genes is shown in Tables S1 and S2). 
(C) Validation of microarray. Real-time RT-PCR analysis of expression of the selected genes is shown. n = 3 mice/genotype. Data are presented as mean ± 
SD (error bars); *, P < 0.05; **, P < 0.01; Student’s t test.
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Figure 5. Effect of miR-214 overexpression on the key regulators of HF morphogenesis. (A, left) Immunofluorescence analysis of -catenin (red) with 
nuclear staining (DAPI, blue). There was a marked decrease of -catenin in hair placode epithelium of DTG mice at E17.5. (A, right) Western blot and its 
densitometry analysis. There were reduced levels of -catenin protein in the skin of DTG mice at P0; data are shown as -catenin band density normalized 
relative to -actin. The data shown are from a single representative experiment out of three repeats. (B) Reduced expression of Lef-1 (red fluorescence) 
in hair placode epithelium and mesenchyme (asterisks) in the skin of DTG mice with nuclear staining (DAPI, blue). (C) More prominent expression of 
pSmad1/5/8 in DTG hair placodes and intrafollicular epidermis versus WT mice (red fluorescence; nuclear staining with DAPI, blue). (D and E) Decreased 
expressions of Shh (D) and Edar (E) in the HF placodes of DTG mice (red/green fluorescence; nuclear staining with DAPI, blue). (F and G) Reduced expres-
sion of Cyclin D1 (F) and Cyclin D2 (G) in the DTG hair placodes and the epidermis (red fluorescence; nuclear staining with DAPI, blue). (H) Quantitative 
immunofluorescence analysis. Immunofluorescence intensity was normalized to the number of DAPI+ cells in the selected areas. n = 3 mice/genotype. Data 
are presented as mean ± SD (error bars); *, P < 0.05; Student’s t test. Broken lines demarcate the examples of the areas used for quantitative immunofluor-
escence analysis. Bars: (A–E) 25 µm; (F and G) 50 µm.
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Figure 6. Effect of miR-214 overexpression on the key regulators of HF cycling. (A and B) Reduced expression of -catenin and Lef-1 (red fluorescence) 
in the hair matrix (arrows) and dermal papilla (asterisks) of DTG follicles (nuclear staining with DAPI, blue). (C) Increased pSmad 1/5/8 expression in 
the postmitotic keratinocytes of the hair bulb and precortex in DTG mice (arrow; red fluorescence; nuclear staining with DAPI, blue). (D) Decrease in Shh 
expression in the hair matrix of DTG mice (arrow; red fluorescence; nuclear staining with DAPI, blue). (E and F) Decreased expression of cyclin D1 (red 
fluorescence) and cyclin-dependent kinase 1 (green fluorescence) in the hair matrix of DTG mice (arrows; nuclear staining with DAPI, blue). (G) Quantita-
tive immunofluorescence analysis. Immunofluorescence intensity was normalized to the number of DAPI+ cells. n = 3 mice/genotype. The broken lines 
demarcate the areas of the examples used for quantitative immunofluorescence analysis. (H, left) Immunodetection of Sox9+ cells in the HF outer root 
sheath (red fluorescence). (H, right) Quantification of Sox9+ cells in the outer root sheath. n = 3 mice/genotype. Data are presented as mean ± SD (error 
bars); *, P < 0.05; **, P < 0.01; Student’s t test. Bars: (A–F) 50 µm; (H) 25 µm.
Dlx3 transcription factor involved in the control of HF kerati-
nocyte differentiation was less pronounced in transgenic HFs 
versus the controls (Fig. S1 J). Overexpression of miR-214 
during the hair cycle was associated with a significant decrease 
in the number of Sox9-positive cells in the outer root sheath, 
which suggests a reduced supply of the progenitor cells from 
the bulge for the hair matrix of actively growing HFs upon 
miR-214 overexpression (Fig. 6 H).
These data suggest that miR-214 exerts inhibitory effects 
on HF development and cycling, at least in part, by regulating 
the activity of key signaling pathways (Wnt, Hedgehog, Bmp, 
and Edar) in keratinocytes, as well as by modulation of Wnt 
signaling in dermal papilla fibroblasts.
-Catenin is a direct target of miR-214  
in keratinocytes
To identify the direct targets of miR-214 in keratinocytes, gene 
expression profiling results obtained from the epithelium of 
neonatal DTG mice after 48 h of Dox activation were linked 
with four databases for prediction of miRNA targets, including 
PITA, miRanda, miRDB, and Targetscan (Rehmsmeier et al., 
2004; Lewis et al., 2005; Kertesz et al., 2007; Wang and El 
Naqa, 2008; Fig. 7 A). The largest number of possible miR-214 
target genes was predicted by PITA and miRanda (192 and 78, 
respectively), whereas TargetScan and miRDB showed only 
18 and 11 possible targets, respectively. Intersections of PITA, 
miRanda, and miRDB predictions identified nine common 
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miR-214 mimic compared with the cells treated with LiCl 
solo (Fig. S1 N).
Collectively, these data suggest that -catenin is a genu-
ine target of miR-214, and that miR-214 is involved in the con-
trol of the activity of the Wnt pathway in keratinocytes.
Activation of Wnt signaling rescues the 
skin phenotype in miR-214 transgenic mice
To further explore the functional links between miR-214 and 
-catenin in vivo, miR-214 transgene was induced after E10.5, 
followed by the subcutaneous injections of Wnt agonist BIO on 
five consecutive days after birth. Although -catenin mRNA 
levels were low in the skin of DTG mice treated with BIO, 
-catenin protein expression was quite similar in the HFs of DTG 
and WT mice (Fig. 8, A and B). This suggests that the reduced 
levels of the -catenin transcript were most likely compensated 
by -catenin protein stabilization caused by the GSK-3 inhibi-
tion induced by BIO (Meijer et al., 2003). Pharmacological ex-
periments revealed that BIO treatment lead to induction of new 
HFs in DTG mice postnatally, which resulted in the appearance 
of the HFs at early stages of morphogenesis (stages 2–3) in 
DTG mice followed by restoration of their total number, similar 
to the WT controls (Fig. 8, C–E). In addition, pharmacological 
Wnt activation resulted in a significant increase of the hair bulb 
diameter in the HFs at advanced stages (stages 6–7) of morpho-
genesis in DTG mice, whereas no increase of the hair bulb size 
was seen in WT mice treated with BIO (Fig. 8 F). These obser-
vations demonstrate that activation of Wnt signaling in DTG 
mice rescues the effects of miR-214 overexpression in vivo, 
confirming further that miR-214 does indeed interfere with Wnt 
pathway activity in the developing and postnatal skin.
Discussion
MicroRNA-dependent control of gene expression plays a fun-
damental role in the balancing and fine-tuning of lineage-
specific differentiation programs in many organs, including skin 
(Andl et al., 2006; Yi et al., 2006). In this paper, we identify a 
novel role for miR-214 in the control of skin and HF develop-
ment, and demonstrate that: (1) miR-214 shows spatial-temporal 
changes in the expression pattern in the skin during HF morpho-
genesis and cycling; (2) inducible overexpression of miR-214 
in keratinocytes inhibits cell proliferation, and results in a for-
mation of fewer HFs with decreased size of the hair bulb, which 
produce thinner hair; (3) miR-214 regulates the balance in the ac-
tivities of multiple signaling pathways, including Wnt, Shh, Edar, 
and Bmp, in developing and postnatal skin; and (4) -catenin 
serves as a direct miR-214 target in keratinocytes.
During skin development and postnatal growth, miR-
214 expression predominates in differentiating populations of 
keratinocytes committed either to epidermal or HF cell fates 
(suprabasal epidermal or hair matrix keratinocytes, respectively), 
whereas its expression in the progenitor cell populations of the 
basal epidermal layer or HF outer root sheath appears to be 
considerably lower. K14-driven miR-214 overexpression in the 
progenitor cell populations of the epidermis and HF results in a 
reduced epidermal proliferation and accelerated differentiation, 
possible miR-214 targets, including Ctnnb1 and Shh (Fig. S1 K). 
However, an overlap of all four databases revealed only three 
predicted target genes for miR-214, whose expression was al-
tered in keratinocytes of DTG mice, including Ctnnb1, but not 
Shh (Fig. 7 A and Fig. S1 K).
To validate the results of bioinformatic analysis and ex-
plore whether -catenin and Shh 3 UTRs carry functional 
binding sites for miR-214 (Fig. 7 B and Fig. 1 L), the luciferase 
reporter assay was performed. Cotransfection of HaCaT cells 
with miR-214 mimic and the -catenin 3 UTR reporter con-
struct caused significant reduction in luciferase activity, com-
pared with the corresponding control, whereas this effect was 
not detected when -catenin 3 UTR was mutated (Fig. 7 C), 
thus confirming that -catenin is a direct target of miR-214. 
However, the luciferase reporter assay did not confirm the di-
rect interactions between miR-214 and 3 UTR of Shh, which 
suggests that a decrease of its expression in the HFs after 
miR-214 overexpression is a secondary effect mediated by other 
factors (Fig. S1 M).
Next, the effect of miR-214 on the -catenin/Tcf-dependent 
transcription activity was evaluated by using the TOPflash 
reporter assay. A significant induction in TOPflash reporter ac-
tivity, without any effect on FOPflash activity (negative con-
trol), was detected in HaCaT cells treated with a synthetic Wnt 
agonist 6-bromoindirubin-3-oxime (BIO; Meijer et al., 2003; 
Sato et al., 2004), whereas transfection of cells with miR-214 
mimic significantly diminished TOPflash activity induced by 
BIO (Fig. 7 D).
Simultaneous in situ hybridization for miR-214 and 
immunofluorescence detection of -catenin revealed a predomi-
nantly reciprocal expression pattern of miR-214 and -catenin 
in the epidermis: miR-214 was seen in the suprabasal layer, 
whereas -catenin was more strongly expressed in the basal 
cells (Fig. 7 E). A more complex pattern of miR-214 and 
-catenin expressions was observed in the HFs: clear colocal-
ization of miR-214 and -catenin was seen in undifferentiated 
proliferating cells of the developing HFs and anagen hair ma-
trix, whereas -catenin was not coexpressed with miR-214 in 
the differentiating cells of the precortex (Fig. 7 E).
Furthermore, transfection of primary mouse epidermal 
keratinocytes (PMEKs) with either miR-214 mimic or its 
specific inhibitor resulted in the decrease and increase of the 
-catenin mRNA expression, respectively (Fig. 7 F). Also, 
miR-214 mimic reduced levels of -catenin protein in the 
keratinocytes (Fig. 7 G). miR-214 was also capable of inter-
fering with the activity of Wnt signaling in keratinocytes in-
duced by the GSK-3 inhibitor lithium chloride (LiCl; Klein 
and Melton, 1996; Fig. 7 H). Immunofluorescence analysis 
confirmed that miR-214 mimic decreases nuclear and cyto-
plasmic -catenin protein levels compared with the control. 
Moreover, miR-214 abrogated LiCl-induced -catenin ex-
pression: both nuclear and cytoplasmic -catenin levels were 
significantly decreased in the keratinocytes synergistically 
treated with LiCl and miR-214 mimic compared with the 
cells treated with LiCl alone (Fig. 7 H). Consistent with this 
observation, Western blot analysis showed reduced levels 
of -catenin in the keratinocytes cotreated with LiCl and 
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Figure 7. miR-214 modulates the activity of Wnt signaling by targeting -catenin. (A) A Venn diagram depicting the overlap of four databases for pre-
diction of miR-214 targets (PITA, miRanda, miRDB, and Targetscan) with gene expression profiling in the epithelium of neonatal DTG and WT mice after 
48 h of Dox treatment. Only down-regulated genes (<1.5-fold) were included in the analysis. (B) Predicted interactions between miR-214 and Ctnnb1. 
Alignment of mouse and human sequences in the 3 UTR of Ctnnb1 mRNA is shown. (C) Significant reduction in luciferase activity in HaCaT cells due 
to cotransfection with miR-214 mimic and the Ctnnb1 3 UTR construct encompassing the putative miR-214 target site. No changes in luciferase activity 
were detected when the miRNA binding site was mutated (mut-3UTR). Each sample was normalized to Renilla luciferase activity. The data shown are 
from a single representative experiment out of three repeats. For the experiment shown, n = 3 for all experimental conditions. (D) TOPflash reporter assay. 
There was significant induction in TOPflash reporter activity in HaCaT cells by BIO, which was diminished by miR-214 mimic. There were no changes in 
FOPflash activity in any experimental groups. The data shown are from a single representative experiment out of three repeats. For the experiment shown, 
n = 3. (E) Dual fluorescent in situ hybridization for miR-214 (red) and immunofluorescence of -catenin (green). -Catenin is expressed in the basal layer 
(arrowhead), while more prominent miR-214 expression was seen in the suprabasal cells of the E17.5 epidermis (arrow). There was coexpression of 
miR-214 and -catenin in the developing HF (stage 3 morphogenesis) and anagen VI hair matrix (arrows). There was also a lack of miR-214 in -catenin+ 
differentiating cells of the precortex (arrowhead). The broken line demarcates the epidermal–dermal border. (F) Real-time RT-PCR. -Catenin expression 
in primary epidermal keratinocytes transfected with either miR-214 mimic or miR-214 inhibitor is shown. The data shown are from a single representative 
experiment out of three repeats. For the experiment shown, n = 3. (G) Western blot and its densitometry analysis. There were reduced levels of -catenin 
protein in primary epidermal keratinocytes transfected with miR-214 mimic. Data are shown as -catenin band density normalized relative to -actin. The 
data shown are from a single representative experiment out of three repeats. (H) Immunocytochemistry and quantitative immunofluorescence. There was 
prominent -catenin staining (red) in primary epidermal keratinocytes treated with the GSK-3 inhibitor LiCl compared with the control, and decreased 
-catenin staining in the nucleus of keratinocytes transfected with miR-214 mimic and synergistically exposed to miR-214 mimic and LiCl. The data shown 
are from a single representative experiment out of three repeats. For the experiment shown, n = 3. Data are presented as mean ± SD (error bars); *, P < 0.05; 
**, P < 0.001; ***, P < 0.0001; Student’s t test. Bars: (E) 50 µm; (H) 5 µm.
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Sick et al., 2006). In turn, FGF and Edar pathways promote 
the placode cell fate, at least in part, by inhibiting the activity 
of BMP signaling (Eivers et al., 2008; Plouhinec et al., 2011), 
whereas Edar via the NF-kB pathway stimulates expression 
of the BMP antagonists, such as connective tissue growth fac-
tor (CTGF) and Follistatin (Mou et al., 2006). Edar serves as 
a downstream effector of Wnt signaling, which is initially ac-
tivated in preplacodes independently of Edar/NF-B activity, 
whereas later Edar signaling is required to refine the pattern 
of Wnt/-catenin activity via stimulation of expression of the 
Wnt10b in the placode progenitor cells (Zhang et al., 2009). 
In addition, Edar signaling promotes HF placode formation 
by stimulation of Sonic hedgehog expression (Pummila et al., 
2007), which operates as a potent stimulator of keratinocyte 
proliferation in the developing HF (St-Jacques et al., 1998; 
Chiang et al., 1999).
Recent data suggest that the activity of the Wnt signal-
ing pathway varies considerably in distinct skin compartments: 
as well as in formation of 30% fewer HFs with decreased hair 
bulb size and producing thinner hairs.
Skin and HF morphogenesis is controlled by coordinated 
activities of the Wnt, Hedgehog, Edar, Bmp, Fgf, Notch, and 
other signaling pathways (Millar, 2002; Schmidt-Ullrich and 
Paus, 2005; Blanpain and Fuchs, 2009). Among these pathways, 
Wnt signaling operates as the most powerful regulator of skin 
development. It controls cell proliferation in both epithelium 
(epidermis, HF matrix) and mesenchyme, and regulates differen-
tiation of hair matrix keratinocytes and the morphogen-producing 
activity of dermal papilla cells (Zhou et al., 1995; Huelsken 
et al., 2001; Andl et al., 2002; Enshell-Seijffers et al., 2010; 
Choi et al., 2013; Fu and Hsu, 2013; Tsai et al., 2014). In the de-
veloping HFs, the Wnt signaling pathway operates as the acti-
vator of the placode formation, whereas BMP signaling inhibits 
this process and, together with Wnt inhibitors, Dkk1/2/4 pro-
motes the interplacode cell fate in the epidermal progenitor cells 
(Botchkarev et al., 1999; Jiang et al., 1999; Andl et al., 2002; 
Figure 8. Activation of Wnt signaling rescues the skin phenotype in miR-214 transgenic mice. (A) Real-time RT-PCR. There were decreased levels of 
-catenin transcript in the DTG skin treated with BIO versus BIO-treated WT mice. n = 3 mice/genotype. (B) Immunofluorescence analysis of -catenin 
(red) in the HFs of WT and DTG mice treated with Wnt agonist BIO on 5 consecutive days (arrow). The broken lines demarcate the examples of the 
areas used for quantitative immunofluorescence analysis. Bar, 25 µm. (C) Representative microphotographs of back skin histology of WT and DTG 
mice after 5 d of BIO treatment at P5.5. Arrows show HF at 2–3 stages of morphogenesis. Bar, 100 µm. (D) There was a significant reduction in the 
number of HFs in DTG versus WT littermate at P5.5, while there was no difference in HF number between WT and DTG mice after 5 d of BIO treatment. 
Bar, 50 µm. n = 3 mice/genotype. (E) Quantitative analysis of HF at different stages of morphogenesis in the skin of WT and DTG mice after 5 d of 
BIO treatment. n = 3 mice/genotype. (F) Histomorphometric analysis of hair bulb diameter in DTG and WT skin treated with BIO as measured across 
the widest part. n = 3 mice/genotype. Data are presented as mean ± SD (error bars). *, P < 0.05; Student’s t test.
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(St-Jacques et al., 1998; Chiang et al., 1999; Mill et al., 2003; 
Schmidt-Ullrich et al., 2006). Shh also promotes epidermal pro-
liferation (Zhou et al., 2006). In adult mice, Shh is essential for 
anagen onset and proper hair cycling (Sato et al., 1999; Wang 
et al., 2000). However, our experimental data validating the bioin-
formatic prediction suggested that Shh does not serve as a direct 
miR-214 target in the keratinocytes. Given that Wnt signaling 
operates as upstream of Edar and Shh pathways in the con-
trol of the HF placode formation (Schmidt-Ullrich et al., 2006; 
Zhang et al., 2009), these data suggest that down-regulation of 
Edar and Shh expression seen in the HF placodes of miR-214 
DTG mice is, most likely, a result of the indirect effects linked 
to the miR-214–mediated decrease of Wnt signaling activity 
in keratinocytes.
Our data demonstrating that overexpression of miR-214 
results in the development of smaller HFs producing thinner 
hair suggest miR-214 involvement in the control of HF size and 
its relevance to the mechanisms that contribute to HF miniatur-
ization seen in androgenetic alopecia (Garza et al., 2011). How-
ever, additional studies are required to assess the role of 
miR-214 in the control of HF size in human skin, as well as the 
potential involvement of miR-214 in regulation of the activity 
of distinct HF stem cell populations residing in secondary hair 
germ and bulge during hair cycle (Hsu et al., 2011; Rompolas 
and Greco, 2014). Our data suggest that the decrease of HF 
size in K14rtTA/TRE-miR-214 mice could not only be associ-
ated with the decreased proliferation in the hair matrix, but 
also with miR-214 effects on the migration of the progenitor 
cells from the bulge alongside the outer root sheath toward the 
hair matrix.
Indeed, K14rtTA/miR-214 HFs contained significantly 
fewer Sox9+ cells in the outer root sheath. Sox9 is a transcrip-
tional regulator that is expressed in the HF stem cells and their 
outer root sheath progenies, and is required for guiding stem 
cell progenies to the hair matrix (Vidal et al., 2005). Therefore, 
a reduced number of Sox9+ cells in the transgenic follicles sug-
gests the inhibitory action of miR-214 on stem cells and their 
progenies, which contributes to the formation of the smaller 
hair bulbs. However, these effects could also be associated with 
decreased -catenin expression, as -catenin is acting as the up-
stream regulator of Sox9 expression in the intestinal epithelium 
and neural crest cells (Blache et al., 2004; Liu et al., 2013).
In addition to the changes seen in the HF epithelium, a 
significant reduction in the number of dermal papilla cells was 
observed in K14rtTA/miR-214 mice. This is consistent with pre-
viously published data demonstrating that a decrease of the hair 
bulb size is associated with reduced cellularity of the dermal 
papilla (Chi et al., 2013). Similar to mice with conditional ab-
lation of -catenin in the HF mesenchyme (Enshell-Seijffers 
et al., 2010), miR-214 overexpression results in the decrease of 
-catenin, Lef1 expression, and lack of changes in Sox2 in the 
dermal papilla. Therefore, the effects seen in K14rtTA/miR-214 
mice could be a result of the altered epithelial–mesenchymal 
interactions. Also, given that miRNAs are capable of exerting 
paracrine effects on distantly located cellular targets (Zhu and 
Fan, 2011), additional studies are required to clarify whether 
miR-214 overexpression in keratinocytes could directly influence 
low levels of activity are required for maintenance of epider-
mal proliferation, medium level signaling is required for main-
tenance of epithelial–mesenchymal interactions in the hair bulb 
to promote active hair growth phase, and high activity promotes 
hair shaft differentiation (Choi et al., 2013). Our data demon-
strate that miR-214 contributes to the regulation of the activity 
of Wnt signaling in the developing and postnatal skin, at least 
in part, by targeting its key component -catenin: (1) miR-214 
and -catenin exhibit reciprocal expression pattern in the epi-
dermis, whereas miR-214 and -catenin are colocalized in un-
differentiated epithelial cells of the hair peg and in hair matrix 
keratinocytes; (2) -catenin expression is markedly decreased 
in the epidermis, HF placodes, HF matrix, and dermal papilla 
after K14-driven miR-214 overexpression; (3) bioinformatic 
prediction analysis and experimental data confirms direct tar-
geting of -catenin 3 UTR by miR-214 in keratinocytes; and 
(4) miR-214 is capable of interfering with the activity of Wnt 
signaling after its activation by the GSK-3 inhibitors both 
in vitro and in vivo.
Furthermore, the skin phenotype of miR-214 transgenic 
mice (decreased epidermal proliferation, proportional decrease 
in the number of all HF types, decrease of the size of hair bulbs, 
and formation of thinner hair versus the corresponding WT con-
trols) is consistent with the skin phenotype of mice with condi-
tional ablation of -catenin either in keratinocytes or in the 
dermal papilla fibroblasts (Huelsken et al., 2001; Enshell- 
Seijffers et al., 2010; Tsai et al., 2014). Importantly, the key 
features of the skin phenotype in miR-214–overexpressing mice 
(decrease of the HF number and hair bulb size) are rescued by 
pharmacological activation of the Wnt pathway in vivo, thus 
further supporting the links between miR-214 and Wnt pathway 
activity in the skin. These data are also consistent with data 
published previously showing miR-214 targeting of -catenin 
in hepatocellular carcinoma cells (Wang et al., 2012).
The Wnt signaling pathway is a potent regulator of cell pro-
liferation, and many effects of miR-214 on skin and HF develop-
ment are most likely associated with interference with cell cycle 
regulation: indeed, short-term activation of miR-214 (48 h) sup-
pressed the expressions of several cyclins and cyclin-dependent 
kinases, including cyclin B, cyclin D1, cyclin D2, and cdk1. Con-
sistent with these observations, substantial up-regulation in the 
cyclin-dependent kinase inhibitors p16 and p19 was still detected 
in fully developed follicles of the K14rtTA/TRE-miR-214 mice, 
which suggests the activation of the anti-proliferative program 
in response to increased levels of miR-214 in the keratinocytes. 
These data are in line with the results obtained in other models 
demonstrating that miR-214 expression is substantially decreased 
in cutaneous squamous cell carcinoma (Yamane et al., 2013) and 
that the anti-proliferative effects of miR-214 in the myoblast cell 
line are achieved by targeting Nras (Liu et al., 2010).
Reduced cell proliferation seen in the epidermis and 
HFs in K14rtTA/TRE-miR-214 mice could also be a result of 
altered activity of Shh signaling. Indeed, K14rtTA/TRE-miR-214 
mice showed decreased expression of Shh and its signal 
tranducer Smo. Shh signaling is required for post-hair placode 
initiation growth by stimulating proliferation of HF epithelial 
cells via transcriptional activation of cyclin D1 and cyclin D2 
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In situ hybridization, immunofluorescence, and histology
Skin cryosections (10 µm) were fixed in 4% paraformaldehyde for 10 min 
at room temperature. In brief, tissue sections were acetylated in trietha-
nolamine buffer (4.5 mM triethanolamine, 6 M NCl, and 3 mM acetic 
anhydride) for 10 min and permeabilized (1% Triton X-100/1× DEPC-
treated PBS) for 30 min, slides were hybridized with 2.5 pmol DIG-labeled 
miR-214 probe (Exiqon) diluted in hybridization buffer (50% formamide DI, 
2× saline-sodium citrate (SCC), 1% dextran sulfate, and 0.4 mg/ml tRNA) 
for 16–18 h at 55°C overnight. Slides were subsequently washed twice 
in SCC (10 min, 4 times, 65°C), 0.1× SCC (60 min, 65°C), and 0.2× 
SCC (10 min, RT). Immunodetection of miR-214 was performed with sheep 
alkaline phosphatase–conjugated anti-DIG antibody (1:5,000; Roche) fol-
lowed by a staining reaction with NBT/BCIP solution (Roche) for 16–18 h 
at RT. Alternatively, the signal was developed with the Tyramide Signal 
Amplification (TSA) system with FITC-conjugated reagent (PerkinElmer).
For immunofluorescence, the formalin-fixed cryosections or metha-
nol-fixed cells were incubated with primary antisera listed in Table 1 over-
night at 4°C, followed by application of corresponding Alexa Fluor 555 or 
Alexa Fluor 488 antibodies (1:200; Invitrogen) for 45 min at 37°C. Incu-
bation steps were interspersed by washes with PBS. Sections were counter-
stained with DAPI.
For dual fluorescent in situ hybridization and immunofluorescence 
developed with the TSA system, in situ hybridization slides were processed 
for -catenin immunofluorescence as described in the previous paragraph. 
For double immunofluorescence of Keratins and BrdU, the slides were 
treated with DNase I (20 µg/ml; Sigma-Aldrich) for 2 h at 37°C, then incu-
bated with primary antibodies against BrdU (1:500; Abcam), followed by 
subsequent antibody costaining as described in the previous paragraph.
For detection of endogenous alkaline phosphatase, acetone-fixed 
cryosections (10 µm) were incubated in developing solution (100 mM NaCl, 
pH 8.3, 100 mM Tris, pH 9.5, 20 mM HCl, 0.05% Naphtol ASBI phosphate, 
0.5% DMF, 25 mM sodium-nitrite, and 5% New fuchsin) for 15 min, fol-
lowed by a quick wash in PBS and immersion of the slides in Vector Hema-
toxylin Nuclear counterstain solution (Vector Laboratories) for 30 s at RT 
(Botchkareva et al., 1999; Paus et al., 1999).
Microscopy and image analyses
Images were taken at RT using the fluorochromes DAPI, Alexa Fluor 488 
(green), and Alexa Fluor 555 (red). Fluorescence images were acquired 
with a microscope (Eclipse50i) equipped with a Plan Fluor 20×/0.50 NA 
or 40×/0.75 NA objective lens (Nikon), a camera (EXi Aqua; QImaging), 
and Image-Pro Express software (version 6.3; Media Cybernetics). Bright-
field microscopy was performed using a microscope (Eclipse 50i; Nikon) 
equipped with a Plan Fluor 20×/0.50 NA or 40×/0.75 NA objective 
lens (Nikon), a camera (VisiCam 3.0; VWR International), and Visi-Cam 
Image Analyzer software (VWR International). No imaging medium was 
used. For the illustration purposes, images of the skin cryosections were 
adjusted using the levels and brightness/contrast tools in Photoshop 
(CS6; Adobe); the same adjustments were applied to every pixel in each 
RGB channel.
Microarray and real-time PCR
Newborn K14-rtTA/TRE-miR-214 and WT mice were treated with Dox for 
48 h to induce miR-214 followed by skin harvesting. Skins were treated 
with dispase at 37°C for 30 min to collect epidermis and HF epithelium. 
Total RNA was isolated by TRIzol (Sigma-Aldrich) and processed for micro-
array analysis by using 41K Whole Mouse Genome 60-mer oligo-microarray 
(Agilent Technologies). Expression of miR-214 was determined using Taq-
Man real-time PCR Assay (Applied Biosystems) under the following cycling 
conditions: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 
60°C for 60 s.
Differences between samples and controls were calculated based 
on the Ct (Ct) method and normalized to the small nucleolar RNA 202 
values (SnoRNA). Data were pooled, the means ± SD were calculated, 
and statistical analysis was performed using an unpaired Student’s t test. 
Quantitative RT-PCR for mRNA was performed with iQ SYBR Green Super-
mix (Bio-Rad Laboratories), using 10 ng cDNA and 1 µM primers. PCR 
primers were designed with Beacon Designer software (Premier Biosoft 
International; Table 2). Amplification was performed at the following con-
ditions: 95°C for 5 min, followed by 40 cycles of denaturation (95°C 
for 15 s), annealing (30 s at temperature experimentally determined for 
each primer pairs), and elongation (72°C for 15 s). Data analysis was 
performed as described above. Differences between samples and controls 
were calculated based on the Ct (Ct) method and normalized to -actin. 
Statistical analysis was performed using an unpaired Student’s t test.
cell number and gene expression in dermal papilla fibroblasts, 
or if other paracrine factors released from keratinocytes affect 
traffic of the connective tissue progenitor cells to populate dermal 
papilla and/or their activity in the HFs in K14rtTA/miR-214 mice.
Additional studies are also required to define the up-
stream regulators that control miR-214 expression in the dif-
ferent cell types in the skin. For example, it has previously 
been shown that Twist1 transcriptionally regulates miR-214 
expression in specific neural cell populations (Lee et al., 2009); 
however, a role of Twist1 in skin development and HF cycling 
remains unknown and needs to be carefully explored. Identifi-
cation of the miR-214 upstream regulators in skin will help to 
recognize novel players in the miRNA-mediated gene regula-
tory circuits controlling keratinocyte proliferation and differ-
entiation in the developing and postnatal skin.
In summary, our data reveal that miR-214 is a key deter-
minant that controls the activity of the Wnt signaling pathway 
and -catenin expression in the developing and postnatal skin 
and HFs. Because Wnt signaling plays a crucial role in the con-
trol of stem cell activity in many organs during development 
and regeneration, while its uncontrolled activation results in 
tumorigenesis (Chan et al., 1999; Malanchi et al., 2008), these 
data provide an important foundation for further analyses of the 
role of miR-214 as a regulator of Wnt pathway activity in many 
areas of research, including stem cell and cancer biology, re-
generative medicine, and aging.
Materials and methods
Generation of transgenic mice
Animal studies were performed under protocols approved by Boston Uni-
versity and Home Office Project License (UK). K14-rtTA/TRE-miR-214 mice 
were generated on an FVB background. To generate TRE-miR-214 con-
struct, a DNA fragment containing the precursor-mmu-miR-214 coding se-
quence was isolated from pCMV-miR-214 plasmid DNA (SC400919; 
OriGene) followed by blunt-end ligation into the pSTblue-1 vector (EMD 
Millipore). This fragment was then excised and ligated into BamHI–SalI 
sites of the pTRE2-Dual 2 plasmid (Takara Bio Inc.), which contains a pTight 
promoter consisting of a modified minimal CMV promoter, and seven di-
rect repeats of a 36-bp regulatory sequence that contains the 19-bp tet- 
operator sequence, mCherry, and an internal ribosome entry site (IRES2). 
All cloning was verified by sequencing. A PspxI fragment from TRE-miR-214 
construct was purified and pronuclear injections were performed in the 
Transgenic Core at the Boston University School of Medicine using FVB/NJ 
mice as a genetic background. Founders were identified by PCR using trans-
gene promoter–specific DNA primers: forward, 5-GTTCATGTACGGCTC-
CAAG-3; and reverse, 5-CGCAGCTTCACCTTGTAG-3. To generate double- 
transgenic K14-rtTA/TRE-miR-214 mice, TRE-miR-214 mice were crossed 
with K14-rtTA according to standard protocols. To activate expression of tet/ 
Dox-responsive transgenes, mice were fed chow containing 625 mg Dox/kg 
chow (Harlan Laboratories, Inc.). For activation of Wnt signaling, BIO (R&D 
Systems) was administered subcutaneously to back skin of neonatal mice in 
a concentration 2 µg/g (Gunn et al., 2011; Kwon et al., 2014) during five 
constitutive days starting from day 0 after birth.
Genotyping
Genotyping was performed using the following primers and PCR parame-
ters. For K14rtTA mouse genotyping, primer sequences used were provided 
by The Jackson Laboratory, including forward primer oIMR7862, 5-CAC-
GATACACCTGACTAGCTGGGTG-3; and reverse primer oIMR7863, 
5-CATCACCCACAGGCTAGCGCCAACT-3 (PCR parameters: 94°C for 
3 min [94°C for 30 s, 67°C for 60 s, 72°C for 60 s] for 35 cycles, 72°C for 
2 min). For TRE-miR-214 mice, the forward primer, 5-AGAACGTATGTC-
GAGGTAG-3; and reverse primer, 5-TTGGAGCCGTACATGAAC-3 were 
used (PCR parameters: 94°C for 3 min [94°C for 30 s, 67°C for 60 s, 72°C 
for 60 s] for 35 cycles, 72°C for 2 min).
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length was calculated using sections from dorsal skin of K14-rtTA/TRE-
miR-214 and WT samples at the different developmental points, including 
E17.5, P0.5, and P8.5.5 (n = 3 per each experimental group). Prolifera-
tion in the epidermis was assessed by the calculation of the ratio of the 
number of Ki67+ cells to DAPI+ cells in 50–60 microscopic fields. Prolif-
eration in the HF was assessed by calculating the ratio of pH3(Ser28)+ to 
DAPI+ cells per hair bulb in 50–60 HFs of either K14-rtTA/TRE-miR-214 
or WT mice. The hair bulb diameter was measured across the widest part 
of the bulb (Auber line). Altogether, HFs in 50–60 microscopic fields from 
distinct time points were analyzed and compared with a corresponding 
number of HF from the appropriate age-matched WT mice. Comparative 
analysis of Sox9+ cells was done by evaluating the ratio of the number 
Sox9+ to DAPI+ cells in the outer root sheath (from the distal end of the 
bulb to the sebaceous duct). In total, 50–60 follicles of either WT or K14-
rtTA/TRE-miR-214 mice were included in the analysis. Data were pooled, 
the means ± SD were calculated, and statistical analysis was performed 
using an unpaired Student’s t test.
For the assessment of the hair shaft length and width of the four HF 
types (guard, awl, auchene, and zigzag), hairs were plucked from the back 
skin of K14rtTA/TRE-miR-214 (n = 4) and WT mice (n = 4) in the telogen 
Western blot analysis
5 µg of protein was extracted from snap-frozen skin samples or cultured 
cells with lysis buffer consisting of 50 mm Tris-HCl, 1% NP-40, 0.25% 
sodium deoxycholate, 150 mm NaCl, 1 mm EDTA, pH 7.4, and Complete 
Ultra protease inhibitor cocktail (Roche). Protein concentrations were de-
termined using the Bradford assay. Proteins were resolved via SDS-PAGE. 
Membranes were incubated with primary antibodies against -catenin 
(1:2,000) and -actin (1:2,000; Table 1) overnight at 4°C. Horseradish 
peroxidase-tagged IgG antibody was used as a secondary antibody 
(1:5,000; Thermo Fisher Scientific). Antibody binding was visualized with 
an enhanced chemiluminescence system (SuperSignal West Pico kit; Thermo 
Fisher Scientific) and the Gel Doc XR+ system (Bio-Rad Laboratories). Den-
sitometric analysis was performed using ImageJ software (National Insti-
tutes of Health).
Histomorphometry, quantitative immunofluorescence,  
and statistical analysis
For histomorphometry analysis, every tenth cryosection of dorsal skin from 
K14-rtTA/TRE-miR-214 and WT mice was used to exclude the repetitive 
evaluation of the same HF. The number of HFs per millimeter of epidermal 
Table 1. Primary antibodies and associated dilutions
Antibody Host Dilution Source
-Catenin Rabbit 1:2,000 Abcam
BrdU Sheep 1:100 Abcam
CD34 Goat 1:200 BD
Cyclin D1 Rabbit 1:100 Abcam
Cyclin D2 Rabbit 1:100 Abcam
Cdk1 mouse 1:100 Abcam
Cytokeratin 10 Rabbit 1:500 Abcam
Cytokeratin 14 Guinea pig 1:500 Acris
Dlx3 Goat 1:500 Santa Cruz Biotechnology, Inc.
Edar Goat 1:500 R&D Systems
Ki67 Rabbit 1:100 Abcam
Lef-1 Rabbit 1:100 Cell Signaling Technology
Lhx2 Goat 1:200 Santa Cruz Biotechnology, Inc.
Loricin Rabbit 1:100 Abcam
Phospho-H3 Rabbit 1:100 Cell Signaling Technology
Phospho-Smad 1/5/8 Rabbit 1:500 Abcam
Sox 2 Goat 1:200 Santa Cruz Biotechnology, Inc.
Sox 9 Rabbit 1:250 Santa Cruz Biotechnology, Inc.
Shh Rabbit 1:100 Santa Cruz Biotechnology, Inc.
Table 2. List of primers used for RT-qPCR
Gene Accession Sense sequence (5-3) Anti-sense sequence (5-3)
Axin Axin2 NM_015732 CACCTCTCCTCTGTTACCTTC GTCAACGCTCTGCCCTAC
Actb Actin,  NM_007393 TTCCAGCCTTCCTTCTTG GGAGCCAGAGCAGTAATC
Ctnnb1 Catenin, 1 NM_001165902 GCCACCAAACAGATACATAC CCTCTCAGCAACTCTACAG
Cdkn2a Cyclin-dependent kinase inhibitor 2A NM_009877 GCTCTTTGTGTTCCGCTG CTCTGCTCTTGGGATTGG
Cdkn2d Cyclin-dependent kinase inhibitor 2D (p19) NM_009878 GGCTCCTACAGGCAACAG TAGATGGCTCACACTTCAGG
Ccnd1 Cyclin D1 NM_007631 GAGACCATTCCCTTGACTGC GAAATGAACTTCACATCTGTGGC
Ccnd2 Cyclin D2 NM_009829 GGATGCTAGAGGTCTGTGAGG CCAACACTACCAGTTCCCAC
Ccnb1 Cyclin B1 NM_172301 ATAATCCCTCTCCAAGCCCG CTGCTCTTCCTCCAGTTGTC
Cdk1 Cyclin-dependent kinase 1 NM_007659 ATCAGACTTGAAAGCGAGGA GGTGTAAGTAACTCTTAACGAGTG
Edar Ectodysplasin-A receptor NM_010100 GCCCCACCGAGTTGCCGTTT CCAGCCGCTCGATCTGCACC
Krt10 Keratin 10 NM_010660 AGTCTGAAATCACTGAATTG ATCTGGCTTTGAATCTGG
Lef-1 Lymphoid enhancer binding factor 1 NM_001276402 ACTCCAAGCAAGGCATGTC GGGTGATCTGTCCAACGC
Lor Loricrin NM_008508 TTCCAAACCCTTCACATTTTAAG GGGAGGTAGTCATTCAGAAAC
Ptch2 Patched homologue 2 NM_008958 TCCGCACCTCATATCCTAGC CTGTCTCAATTACAGCCACTCG
Smo Smoothened homologue NM_176996 GCTGGAGTAGTCTGGTTCGT GAGTCTCCATCTACCTGAGCC
Sostdc1 Sclerostin domain containing 1 NM_025312 CTTCCTCCTGCCATTCATCTC GAACTCGACTGTTTCGATCCAG
Shh Sonic hedgehog NM_009170 GTTTATTCCCAACGTAGCCGA CTTGTCTTTGCACCTCTGAGTC
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TOPFlash and FOPFlash Wnt reporter assays
HaCaT cells were seeded onto 12-well dishes 24 h before transfection. 
At 80% confluence, a TOPFlash Wnt reporter plasmid (plasmid 12456; 
Addgene) were transfected into each well in combination with (1) control 
oligonucleotide (200 nM), (2) 10 µM of BIO (R&D Systems), (3) pro–miR-
214 (200 nM), and (4) pro–miR-214 (200 nM) and 10 µM BIO (Sato et al., 
1999). Transfection was done using Lipofectamine 2000 (Invitrogen). FOP-
Flash (TOPFlash mutant) reporter plasmid (plasmid 12457; Addgene) was 
used as a control. The cells were cultured for 24 h. The relative luciferase 
activities were determined using the Dual-Gloluciferase assay system (Pro-
mega) on a microplate reader (Infinite 2000; Tecan). All assays were per-
formed in triplicate for three independent trials.
Online supplemental material
Fig. S1 shows additional details of the skin phenotype in K14-rtTA/miR-
214-TRE mice during morphogenesis and the hair cycling, and the results 
of bioinformatic prediction of miR-214 targets in the keratinocytes and their 
validation. Tables S1 and S2 list the genes with down- and up-regulated ex-
pression in the skin epithelium of K14-rtTA/miR-214-TRE versus WT mice. 
Online supplemental material is available at http://www.jcb.org/cgi/ 
content/full/jcb.201404001/DC1.
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phase of the hair cycle. The four hair types were distinguished on the basis 
of their hair length, number of kinks, and medulla width (Sharov et al., 
2006). Hair shaft length and width of 250 plucked hair shafts per animal 
were measured using ImageJ software. Data were pooled, the means ± SD 
were calculated, and statistical analysis was performed using an unpaired 
Student’s t test.
The percentage of HFs in different anagen stages was assessed 
and calculated in K14-rtTA/TRE-miR-214 at days 3 and 5 after the depilation- 
induced hair cycle, respectively, as well as in their corresponding WT lit-
termates. All evaluations were performed using accepted, well-defined 
morphological criteria of HFs at early, mid, and late anagen phase based 
on the changes in the shape and size of the hair matrix and the dermal pa-
pilla (Müller-Röver et al., 2001).
Immunofluorescence intensity was determined using ImageJ software, 
as described previously (Ramot et al., 2010). In brief, red or green fluor-
escent signal was collected from experimental tissues in RGB format using the 
same exposure conditions. To measure the fluorescence intensity at each 
pixel, the RGB images were converted to 8-bit grayscale format. Regions 
of interest of distinct size within the WT and DTG HFs were selected, and 
the mean values of intensity were calculated for each selected areas fol-
lowed by the normalization relative to the number of DAPI+ cells.
Cell culture and transfections
PMEKs were prepared from newborn mice at P2–3. In brief, mouse skins 
were incubated in 0.25% trypsin at 4°C overnight. The epidermal portion 
was minced and filtered through a 70-µm cell strainer (BD Biosciences), 
which result in a single-cell suspension. PMEKs were grown in EMEM cal-
cium-free medium (Lonza) supplemented with 0.05 mM calcium, at 33°C, 
8% CO2 (Scientific Laboratory Suppliers, Hessle, UK) until 60–70% conflu-
ent. PMEKs were transfected with 200 nM of synthetic miR-214 inhibitor 
(anti-miR-214), miR-214 mimic (pro-miR-214), or miRNA negative controls 
(GE Healthcare), using Lipofectamine RNAiMax (Invitrogen). Cells were 
harvested 24 h after transfection and used for further analyses. To induce 
Wnt signaling, PMEKs were treated with 10 mM lithium chloride (Klein 
and Melton, 1996). To examine the regulatory effects of miR-214 on 
Wnt/-Catenin signaling, PMEKs were treated with 10 mM LiCl for 2 h, 
followed by transfection of cells with 200 nM pro-miR-214 or miRNA nega-
tive controls for 4 h at 33°C, 8% CO2. Cells were then harvested 24 h 
after transfection.
miRNA binding predictions
MiR-214 binding was estimated as a consensus from four different predic-
tion algorithms: TargetScan (http://www.targetscan.org/) predicts biolog-
ical targets of miRNAs by searching for the presence of conserved sites that 
match the seed region of each miRNA; miRBase (http://microrna.sanger.
ac.uk) uses the miRanda algorithm to predict miRNA-mRNA pairs; miRDB 
(http://mirdb.org/miRDB) uses the MirTarget2 algorithm, which was de-
veloped by analyzing thousands of genes impacted by miRNAs; and PITA 
(http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html) confirms can-
didates predicted by the other three algorithms.
Luciferase reporter assay
HaCaT cells were grown in Dulbecco’s modified Eagle’s medium (Invi-
trogen) supplemented with heat-inactivated 10% FBS in an atmosphere 
of 5% CO2 at 37°C, until 60–70% confluent. 3 UTR fragments of 
-catenin and Shh containing miR-214 putative target sites were am-
plified from mouse genomic DNA using forward and reverse primers 
containing XhoI and NotI restriction sequences, respectively. For 3 UTR 
of -catenin fragment, 5-CGAGGAGTAACAATACAAATGG-3 and 
5-CAGGTTCACTAGAACATAACAC-3 forward and reverse primers, 
respectively, were used. To amplify a fragment of the 3 UTR of Shh, 
5-ATGAACGGACCTTCAAGAGC-3 and 5-GCATAGCAGGAGAG-
GAATGC-3 primers were used. The amplified fragments were cloned 
at XhoI and NotI sites downstream of CV40 promoter-driven Renilla 
luciferase cassette in pCHECK2 (Promega). Site-directed mutagenesis 
was performed using a QuikChange II XL Site-Directed Mutagenesis kit 
(Agilent Technologies) to mutate the -catenin binding site according 
to the manufacturer’s instructions. For the dual luciferase assay, these 
constructs (200 ng) were cotransfected with 200 nM miR-214 mimic or 
negative control mimic (GE Healthcare) into HaCaT cells using 0.5 µl 
Lipofectamine 2000 (Invitrogen) in 96-well plates. At 24 h after trans-
fection, the relative luciferase activities were determined using Dual-Glo 
Luciferase Assay System (Promega). Assay was performed in triplicate 
for three independent trials.
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Figure S1.   Characterization of  the  skin phenotype  in K14-rtTA/miR-214-TRE mice and validation of miR-214 predicted  targets  in  the keratinocytes.  
(A) Real-time RT-PCR. There was a significant increase in Lor but not K10 expression in the neonatal back skin epithelium of the DTG versus WT mice. n = 3 
mice/genotype. (B–D) Induction of miR-214 transgene by Dox after E10. (B) A comparison of HF length in DTG and WT mice at P8. Significantly shorter 
HFs were seen in the DTG versus WT mice. n = 3 mice/genotype. (C) Significantly reduced total skin in DTG versus WT mice at P8. n = 3 mice/genotype. 
(D) Length of different hair shaft types (in micrometers) in DTG and WT mice plucked at P20, the time of the first telogen phase. No differences were 
found. n = 4 mice/genotype. (E) Immunofluorescence detection of active caspase-3 (red) with nuclear staining (DAPI, blue) in anagen HFs. No difference 
in a-caspase-3 between DTG and WT HFs was detected. (F) Real-time RT-PCR. A significant decrease in Shh transcript levels in skin of DTG versus WT 
mice was seen at E17 after miR-214 induction by Dox after E10. n = 3 mice/genotype. (G) Immunofluorescence analysis of Cyclin d1 expression in the 
epidermis. There was a significant decrease in the number of Cyclin D1+ cells in the DTG epidermis versus WT mice. (H) Immunofluorescence analysis 
of Lhx2 and Sox9 (red) with nuclear staining (DAPI, blue) in HF placodes of DTG and WT mice at E17. No difference in Lhx2 and Sox9 expression was 
detected. (I) Immunodetection of Sox2 (red) with nuclear staining (DAPI, blue) in the dermal papilla of anagen DTG and WT HFs after overexpression of 
miR-214 in telogen skin. No difference in Sox2 staining was observed. (J) Immunodetection of Dlx3 (green) with nuclear staining (DAPI, blue) in the anagen 
DTG and WT HFs after overexpression of miR-214 in telogen skin. There was a decrease in Dlx3 expression in the DTG HFs. (K) Bioinformatic analysis of 
predicted miR-214 target genes that are differentially expressed in DTG epithelium after 48 h of Dox activation. (L) Predicted interactions between miR-214 
and Shh. The alignment of the mouse miR-214 sequence in the 3 UTR of Shh mRNA is shown. (M) There were no changes in luciferase activity in HaCaT 
cells due to cotransfection with miR-214 mimic and the Shh 3 UTR constructs encompassing the putative miR-214 target site. The data shown are from a 
single representative experiment out of three repeats. For the experiment shown, n = 2. (N) Western blot. There were reduced -catenin levels in primary 
epidermal keratinocytes transfected with miR-214 compared with the control, as well as reduced -catenin levels in the keratinocytes cotreated with LiCl 
and miR-214 mimic compared to the cells treated with LiCl alone. Data are presented as mean ± SD (error bars); *, P < 0.05; **P < 0.001; Student’s 
t test. Bars: (E, G, and H) 25 µm; (I and J) 50 µm.
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Table S1 - Genes that show 2-fold down-regulation in the keratinocytes of 
K14rtTA/TRE-miR-214 mice versus WT mice 
 
Accession 
Number Gene name Symbol 
Fold 
change 
    
 Adhesion/Extracellular matrix   
NM_011302 retinoschisis (X-linked, juvenile) 1 Rs1 5.25 
NM_178596 gap junction protein, delta 3 Gjd3 4.73 
NM_010708 lectin, galactose binding, soluble 9, transcript variant 1 Lgals9 4.27 
NM_010327 glycoprotein Ib, beta polypeptide, transcript variant 2 Gp1bb 3.93 
NM_010577 integrin alpha 5 Itga5 3.73 
NM_181277 collagen, type XIV, alpha 1 Col14a1 3.15 
NM_001081249 versican, transcript variant 1 Vcan 2.90 
NM_020486 basal cell adhesion molecule Bcam 2.77 
NM_021334 integrin alpha X Itgax 2.72 
NM_146007 collagen, type VI, alpha 2 Col6a2 2.68 
NM_010386 histocompatibility 2, class II, locus DMa H2-DMa 2.64 
NM_013565 integrin alpha 3 Itga3 2.58 
NM_011150 lectin, galactoside-binding, soluble, 3 binding protein Lgals3bp 2.56 
NM_023051 calsyntenin 1 Clstn1 2.50 
NM_007992 fibulin 2, transcript variant 1 Fbln2 2.44 
NM_178685 protocadherin 20 Pcdh20 2.43 
NM_010181 fibrillin 2 Fbn2 2.35 
NM_001082960 integrin alpha M, transcript variant 1 Itgam 2.32 
NM_013552 hyaluronan mediated motility receptor (RHAMM) Hmmr 2.18 
NM_010180 fibulin 1 Fbln1 2.01 
    
 Cell Cycle/Apoptosis   
NM_018754 stratifin Sfn 3.34 
NM_177372 DNA replication helicase 2 homolog Dna2 3.28 
NM_007631 cyclin D1* Ccnd1 3.76 
NM_008564 minichromosome maintenance deficient 2 mitotin Mcm2 2.91 
NM_028131 centromere protein N Cenpn 2.88 
NM_010059 
DMC1 dosage suppressor of mck1 homolog, meiosis-specific 
homologous recombination Dmc1 2.78 
NM_028222 cyclin-dependent kinase inhibitor 3 Cdkn3 2.72 
NM_008014 
protein phosphatase 1G (formerly 2C), magnesium-
dependent, gamma isoform Ppm1g 2.65 
NM_027263 apoptosis-inducing, TAF9-like domain 1 Apitd1 2.60 
NM_001012273 baculoviral IAP repeat-containing 5, transcript variant 3 Birc5 2.51 
NM_198654 NSL1, MIND kinetochore complex component, homolog Nsl1 2.50 
NM_011015 origin recognition complex, subunit 1, transcript variant A Orc1 2.43 
NM_027954 
synaptonemal complex central element protein 2, transcript 
variant 2 Syce2 2.42 
NM_019499 MAD2 mitotic arrest deficient-like 1 Mad2l1 2.33 
NM_022654 leucine-rich and death domain containing Lrdd 2.33 
NM_008566 
minichromosome maintenance deficient 5, cell division cycle 
46 Mcm5 2.29 
NM_026560 cell division cycle associated 8 Cdca8 2.28 
NM_009828 cyclin A2 Ccna2 2.27 
NM_198605 spindle and kinetochore associated complex subunit 3 Ska3 2.26 
NM_001042421 kinetochore associated 1 Kntc1 2.25 
NM_146235 
excision repair cross-complementing rodent repair deficiency 
complementation group 6 like Ercc6l 2.23 
NM_001159930 centromere protein L , transcript variant 1 Cenpl 2.19 
NM_007900 ect2 oncogene, transcript variant 1 Ect2 2.18 
NM_007659 cyclin-dependent kinase 1* Cdk1 2.64 
NM_013929 SIVA1, apoptosis-inducing factor, transcript variant 1 Siva1 2.15 
NM_011049 cyclin-dependent kinase 16 Cdk16 2.15 
NM_172301 cyclin B1* Ccnb1 2.36 
NM_001014976 extra spindle poles-like 1 Espl1 2.15 
NM_025995 F-box protein 5 Fbxo5 2.14 
NM_011799 cell division cycle 6, transcript variant 1 Cdc6 2.07 
NM_027290 minichromosome maintenance deficient 10 Mcm10 2.05 
NM_025866 cell division cycle associated 7 Cdca7 2.05 
NM_016681 checkpoint kinase 2 Chek2 2.04 
NM_175554 claspin Clspn 2.03 
NM_008567 minichromosome maintenance deficient 6 Mcm6 2.03 
NM_007630 cyclin B2 Ccnb2 2.02 
NM_010790 maternal embryonic leucine zipper kinase Melk 2.01 
NM_009829 Cyclin D2* 
Ccnd2 1.49 
 Chromatin remodelling   
NM_178215 histone cluster 2, H3b Hist2h3b 4.50 
NM_007928 
MAP/microtubule affinity-regulating kinase 2, transcript 
variant 1 Mark2 4.42 
NM_175654 histone cluster 1, H4d Hist1h4d 4.24 
NM_178211 histone cluster 1, H4k Hist1h4k 4.04 
NM_178210 histone cluster 1, H4j Hist1h4j 4.00 
NM_178208 histone cluster 1, H4c Hist1h4c 3.91 
NM_175652 histone cluster 4, H4 Hist4h4 3.84 
NM_001080819 AT rich interactive domain 1A Arid1a 3.77 
NM_030609 histone cluster 1, H1a Hist1h1a 3.51 
NM_026785 ubiquitin-conjugating enzyme E2C Ube2c 3.39 
NM_020034 histone cluster 1, H1b Hist1h1b 3.39 
NM_015787 histone cluster 1, H1e Hist1h1e 3.28 
NM_033596 histone cluster 2, H4 Hist2h4 3.17 
NM_016957 high mobility group nucleosomal binding domain 2 Hmgn2 3.13 
NM_001195421 histone cluster 1, H4m Hist1h4m 3.01 
NM_013548 histone cluster 1, H3f Hist1h3f 2.90 
NM_145073 histone cluster 1, H3g Hist1h3g 2.84 
NM_010931 
ubiquitin-like, containing PHD and RING finger domains, 1, 
transcript variant 1 Uhrf1 2.72 
NM_175653 histone cluster 1, H3c Hist1h3c 2.66 
NM_178856 GINS complex subunit 2 (Psf2 homolog) Gins2 2.66 
NM_012012 exonuclease 1 Exo1 2.62 
NM_001204973 bromodomain containing 2 , transcript variant 2 Brd2 2.56 
NM_021790 centromere protein K, transcript variant 1 Cenpk 2.55 
NM_175663 histone cluster 1, H2ba Hist1h2ba 2.54 
NM_011234 RAD51 homolog Rad51 2.53 
NM_020022 replication factor C (activator 1) 2 Rfc2 2.51 
NM_178183 histone cluster 1, H2ak Hist1h2ak 2.46 
NM_008210 H3 histone, family 3A H3f3a 2.40 
NM_011623 topoisomerase (DNA) II alpha Top2a 2.38 
NM_001163775 TAO kinase 2, transcript variant 2 Taok2 2.37 
NM_181586 
sirtuin 6 (silent mating type information regulation 2, 
homolog) 6 , transcript variant 1 Sirt6 2.35 
NM_198160 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily c, member 2, transcript 
variant 3 Smarcc2 2.35 
NM_024184 ASF1 anti-silencing function 1 homolog B Asf1b 2.33 
NM_028039 establishment of cohesion 1 homolog 2 Esco2 2.33 
NM_145946 Fanconi anemia, complementation group I Fanci 2.31 
NM_178200 histone cluster 1, H2bm Hist1h2bm 2.24 
NM_009030 retinoblastoma binding protein 4 Rbbp4 2.23 
NM_008894 polymerase (DNA directed), delta 2, regulatory subunit Pold2 2.20 
NM_008228 histone deacetylase 1 Hdac1 2.20 
NM_013883 sex comb on midleg homolog 1, transcript variant 1 Scmh1 2.18 
NM_020004 K(lysine) acetyltransferase 2A, transcript variant 1 Kat2a 2.16 
NM_011121 polo-like kinase 1 Plk1 2.16 
NM_146208 nei like 3 Neil3 2.16 
NM_134083 
regulator of chromosome condensation and BTB (POZ) 
domain containing protein 2 , transcript variant 2 Rcbtb2 2.13 
NM_008892 polymerase (DNA directed), alpha 1 Pola1 2.11 
NM_029797 meiotic nuclear divisions 1 homolog Mnd1 2.10 
NM_013550 histone cluster 1, H3a Hist1h3a 2.10 
NM_010722 lamin B2 Lmnb2 2.09 
NM_026632 replication protein A3 Rpa3 2.08 
NM_153141 
coactivator-associated arginine methyltransferase 1, 
transcript variant 2 Carm1 2.07 
NM_023294 NDC80 homolog, kinetochore complex component Ndc80 2.05 
NM_172453 PIF1 5'-to-3' DNA helicase homolog Pif1 2.05 
NM_009013 RAD51 associated protein 1 Rad51ap1 2.03 
NM_008017 structural maintenance of chromosomes 2 Smc2 1.98 
    
 Cytoskeleton   
NM_011072 profilin 1 Pfn1 3.96 
NM_010669 keratin 6B Krt6b 3.94 
NM_009451 tubulin, beta 4A class IVA Tubb4a 3.93 
NM_001163637 janus kinase and microtubule interacting protein 2 Jakmip2 3.39 
NM_009449 tubulin, alpha 3B Tuba3b 3.34 
NM_008445 kinesin family member 3C Kif3c 2.92 
NM_130857 keratin associated protein 19-3 Krtap19-3 2.92 
NM_183296 keratin associated protein 16-3 Krtap16-3 2.92 
NM_016879 keratin 85 Krt85 2.90 
NM_011526 transgelin Tagln 2.88 
NM_001163615 keratin associated protein 20-2 Krtap20-2 2.81 
NM_130870 keratin associated protein 16-1 Krtap16-1 2.81 
NM_175272 neuron navigator 2, transcript variant 1 Nav2 2.76 
NM_001113406 keratin associated protein 11-1 Krtap11-1 2.70 
NM_019445 formin 2 Fmn2 2.68 
NM_148934 tubulin polyglutamylase complex subunit 1 Tpgs1 2.64 
NM_010672 keratin associated protein 6-1 Krtap6-1 2.64 
NM_028621 keratin associated protein 21-1 Krtap21-1 2.62 
NM_019641 stathmin 1 Stmn1 2.60 
NM_027771 keratin associated protein 7-1 Krtap7-1 2.58 
NM_130873 keratin associated protein 19-4 Krtap19-4 2.57 
NM_010626 kinesin family member 7 Kif7 2.50 
NM_009931 collagen, type IV, alpha 1 Col4a1 2.42 
NM_001024716 TRIO and F-actin binding protein, transcript variant 1 Triobp 2.41 
NM_010662 keratin 13 Krt13 2.38 
NM_026552 
actin related protein 2/3 complex, subunit 4, transcript variant 
1 Arpc4 2.37 
NM_013928 schwannomin interacting protein 1, transcript variant 4 Schip1 2.34 
NM_172946 keratin 222 Krt222 2.32 
NM_011654 tubulin, alpha 1B Tuba1b 2.29 
NM_001166157 keratin 81 Krt81 2.29 
NM_017470 dynein, axonemal, light chain 4 Dnalc4 2.29 
NM_027800 keratin associated protein 2-4 Krtap2-4 2.28 
NM_010676 keratin associated protein 19-5 Krtap19-5 2.27 
NM_212483 keratin 42 Krt42 2.26 
NM_198599 MAP6 domain containing 1 Map6d1 2.25 
NM_197945 ProSAPiP1 protein Prosapip1 2.24 
NM_145575 caldesmon 1 Cald1 2.20 
NM_017464 
neural precursor cell expressed, developmentally down-
regulated gene 9, transcript variant 2 Nedd9 2.19 
NM_019670 diaphanous homolog 3 Diap3 2.18 
NM_080728 myosin, heavy polypeptide 7, cardiac muscle, beta Myh7 2.16 
NM_134471 kinesin family member 2C Kif2c 2.14 
NM_009768 basigin, transcript variant 1 Bsg 2.14 
NM_028390 anillin, actin binding protein Anln 2.13 
NM_001191018 keratin associated protein 22-2 Krtap22-2 2.11 
NM_133851 
nucleolar and spindle associated protein 1, transcript variant 
1 Nusap1 2.05 
NM_178926 
vimentin-type intermediate filament associated coiled-coil 
protein, transcript variant 1 Vmac 2.01 
NM_010675 keratin associated protein 8-1 Krtap8-1 1.98 
    
 Metabolism   
NM_016956 hemoglobin, beta adult minor chain Hbb-b2 14.97 
NM_001080943 zinc finger, DHHC-type containing 22 Zdhhc22 13.25 
NM_009653 aminolevulinic acid synthase 2, erythroid, transcript variant 1 Alas2 8.62 
NM_008220 hemoglobin, beta adult major chain Hbb-b1 8.30 
NM_008218 hemoglobin alpha, adult chain 1 Hba-a1 6.67 
NM_139142 
solute carrier family 6 (neurotransmitter transporter), member 
20A Slc6a20a 5.09 
NM_018763 carbohydrate sulfotransferase 2 Chst2 4.81 
NM_001082975 short chain dehydrogenase/reductase family 39U, member 1 Sdr39u1 4.59 
NM_009464 uncoupling protein 3 (mitochondrial, proton carrier) Ucp3 4.46 
NM_001033270 
solute carrier family 4, sodium bicarbonate cotransporter, 
member 7 Slc4a7 4.43 
NM_011671 uncoupling protein 2 (mitochondrial, proton carrier) Ucp2 4.41 
NM_027093 
NADH dehydrogenase (ubiquinone) complex I, assembly 
factor 5 Ndufaf5 4.39 
NM_001104531 cytochrome P450, family 2, subfamily d, polypeptide 11 Cyp2d11 4.17 
NM_019698 
aldehyde dehydrogenase 18 family, member A1, nuclear 
gene encoding mitochondrial protein, transcript variant 1 Aldh18a1 3.95 
NM_010066 DNA methyltransferase (cytosine-5) 1 , transcript variant 2 Dnmt1 3.94 
NM_001083955 hemoglobin alpha, adult chain 2 Hba-a2 3.58 
NM_010596 
potassium voltage-gated channel, shaker-related subfamily, 
member 7 Kcna7 3.47 
NM_007817 cytochrome P450, family 2, subfamily f, polypeptide 2 Cyp2f2 3.46 
NM_010359 glutathione S-transferase, mu 3 Gstm3 3.37 
NM_175403 malectin Mlec 3.34 
NM_134118 trans-2,3-enoyl-CoA reductase , transcript variant 1 Tecr 3.31 
NM_007807 cytochrome b-245, beta polypeptide Cybb 3.31 
NM_177186 solute carrier family 35, member E2 Slc35e2 3.26 
NM_013784 phosphatidylinositol glycan anchor biosynthesis, class N Pign 3.22 
NM_009034 retinol binding protein 2, cellular Rbp2 3.15 
NM_011371 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 1 
St6galnac
1 3.15 
NM_016966 3-phosphoglycerate dehydrogenase Phgdh 3.09 
NM_009181 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 St8sia2 3.03 
NM_026969 Sec31 homolog A Sec31a 2.98 
NM_001243052 
branched chain aminotransferase 2, mitochondrial, transcript 
variant 2 Bcat2 2.94 
NM_027790 dehydrogenase/reductase member 2 Dhrs2 2.91 
NM_133189 calcium channel, voltage-dependent, gamma subunit 7 Cacng7 2.85 
NM_144845 UDP glycosyltransferases 3 family, polypeptide A2 Ugt3a2 2.84 
NM_008525 aminolevulinate, delta-, dehydratase Alad 2.84 
NM_178788 dCMP deaminase (Dctd), transcript variant 1 Dctd 2.81 
NM_011961 
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2, transcript 
variant 2 Plod2 2.79 
NM_001033175 ceroid-lipofuscinosis, neuronal 6 Cln6 2.78 
NM_213733 aminopeptidase-like 1 Npepl1 2.76 
NM_030601 chloride channel calcium activated 2 Clca2 2.72 
NM_207161 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 Dnph1 2.69 
NM_009437 thiosulfate sulfurtransferase, mitochondrial Tst 2.68 
NM_009723 
ATPase, Ca++ transporting, plasma membrane 2, transcript 
variant 1 Atp2b2 2.67 
NM_019435 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11 Ndufb11 2.65 
NM_009374 transglutaminase 3 Tgm3 2.62 
NM_146198 
solute carrier family 5 (sodium/glucose cotransporter), 
member 11 Slc5a11 2.59 
NM_025412 pyrroline-5-carboxylate reductase-like Pycrl 2.55 
NM_033617 ATPase, H+ transporting, lysosomal V0 subunit B Atp6v0b 2.53 
NM_145603 carboxylesterase 2C Ces2c 2.51 
NM_008631 metallothionein 4 Mt4 2.46 
NM_009272 spermidine synthase Srm 2.41 
NM_001044308 calcium channel, voltage-dependent, alpha 1I subunit Cacna1i 2.40 
NM_009662 arachidonate 5-lipoxygenase Alox5 2.38 
NM_009104 ribonucleotide reductase M2 Rrm2 2.38 
NM_001163359 fidgetin-like 1, transcript variant 1 Fignl1 2.34 
NM_009804 catalase Cat 2.32 
NM_010497 
isocitrate dehydrogenase 1 (NADP+), soluble, transcript 
variant 2 Idh1 2.32 
NM_008826 phosphofructokinase, liver, B-type Pfkl 2.31 
NM_009127 stearoyl-Coenzyme A desaturase 1 Scd1 2.28 
NM_172371 
solute carrier family 16 (monocarboxylic acid transporters), 
member 13 Slc16a13 2.28 
NM_054094 acyl-CoA synthetase medium-chain family member 1 Acsm1 2.27 
NM_025408 alkaline ceramidase 3 Acer3 2.26 
NM_001271544 
solute carrier family 4, sodium bicarbonate cotransporter, 
member 9, transcript variant 1 Slc4a9 2.26 
NM_026764 glutathione S-transferase, mu 4 , transcript variant 1 Gstm4 2.25 
NM_010274 
glycerol phosphate dehydrogenase 2, mitochondrial (Gpd2), 
transcript variant 2 Gpd2 2.24 
NM_010358 glutathione S-transferase, mu 1 Gstm1 2.22 
NM_008278 hydroxyprostaglandin dehydrogenase 15 Hpgd 2.22 
NM_020581 angiopoietin-like 4 Angptl4 2.21 
NM_172117 ectonucleoside triphosphate diphosphohydrolase 6 Entpd6 2.15 
NM_026678 biliverdin reductase A Blvra 2.15 
NM_080440 
solute carrier family 8 (sodium/calcium exchanger), member 
3, transcript variant 2 Slc8a3 2.15 
NM_030262 protein O-fucosyltransferase 2 Pofut2 2.13 
NM_172773 solute carrier family 17 (anion/sugar transporter), member 5 Slc17a5 2.12 
NM_178696 solute carrier family 25, member 44, transcript variant 1 Slc25a44 2.11 
NM_001040699 myotubularin related protein 7 Mtmr7 2.11 
NM_177382 cytochrome P450, family 2, subfamily r, polypeptide 1 Cyp2r1 2.11 
NM_007838 dolichyl-di-phosphooligosaccharide-protein glycotransferase Ddost 2.10 
NM_172609 translocase of outer mitochondrial membrane 22 homolog Tomm22 2.08 
NM_007621 carbonyl reductase 2 Cbr2 2.08 
NM_013541 glutathione S-transferase, pi 1 Gstp1 2.07 
NM_011962 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 Plod3 2.07 
NM_016666 aryl-hydrocarbon receptor-interacting protein Aip 2.06 
NM_007646 CD38 antigen Cd38 2.05 
NM_028638 glutamate decarboxylase-like 1 Gadl1 2.05 
NM_007379 ATP-binding cassette, sub-family A, member 2 Abca2 2.04 
NM_178086 fatty acid 2-hydroxylase Fa2h 2.02 
NM_019501 prenyl (solanesyl) diphosphate synthase, subunit 1 Pdss1 2.01 
NM_008212 hydroxyacyl-Coenzyme A dehydrogenase Hadh 2.01 
NM_026947 enoyl-Coenzyme A delta isomerase 3 Eci3 2.00 
NM_138665 sarcosine dehydrogenase Sardh 2.00 
NM_011977 solute carrier family 27 (fatty acid transporter), member 1 Slc27a1 2.00 
    
 Others   
NM_001201391 hemoglobin subunit beta-1-like Beta-s 29.45 
NM_023900 pleckstrin homology domain containing, family J member 1 Plekhj1 5.60 
NM_011174 proline rich protein HaeIII subfamily 1 Prh1 5.44 
NM_021384 radical S-adenosyl methionine domain containing 2 Rsad2 4.67 
NM_138602 PRA1 domain family 2 Praf2 4.14 
NM_001042451 synuclein, alpha, transcript variant 1 Snca 4.05 
NM_013877 calcium binding protein 5 Cabp5 3.98 
NM_201518 fibronectin leucine rich transmembrane protein 2 Flrt2 3.83 
NM_177994 R3H domain containing 4 R3hdm4 3.80 
NM_001205102 
leucine-rich repeat, immunoglobulin-like and transmembrane 
domains 3 Lrit3 3.76 
NM_018803 synaptotagmin X Syt10 3.74 
NM_029000 GTPase, very large interferon inducible 1, transcript variant 1 Gvin1 3.73 
NM_207105 histocompatibility 2, class II antigen A, beta 1 H2-Ab1 3.62 
NM_080846 HIG1 domain family, member 1B Higd1b 3.60 
NM_001033478 
family with sequence similarity 47, member E, transcript 
variant 1 Fam47e 3.53 
NM_001081418 glioma tumor suppressor candidate region gene 1 Gltscr1 3.53 
NM_145981 phytanoyl-CoA hydroxylase interacting protein Phyhip 3.26 
NM_021898 testis specific gene A8 Tsga8 3.11 
NM_134122 nurim (nuclear envelope membrane protein) Nrm 3.06 
NM_001163614 achaete-scute complex homolog 4 Ascl4 3.04 
NM_020583 interferon-stimulated protein, transcript variant 1 Isg20 2.98 
NM_173862 family with sequence similarity 83, member A Fam83a 2.94 
NM_175427 family with sequence similarity 163, member B Fam163b 2.91 
NM_001082545 stefin A2 Stfa2 2.77 
NM_183187 family with sequence similarity 107, member A Fam107a 2.76 
NM_001142642 fibrosin-like 1, transcript variant 1 Fbrsl1 2.76 
NM_001199631 FK506 binding protein 8, transcript variant 3 Fkbp8 2.75 
NM_172756 ankyrin repeat and LEM domain containing 1 Ankle1 2.75 
NM_133859 olfactomedin-like 3 Olfml3 2.72 
NM_001025576 coiled-coil domain containing 141 Ccdc141 2.71 
NM_025620 RAB15 effector protein Rep15 2.70 
NM_010807 MARCKS-like 1 Marcksl1 2.63 
NM_001081406 leucine rich repeat protein 1 Lrr1 2.51 
NM_018884 PDZ domain containing RING finger 3 Pdzrn3 2.50 
NM_183170 MPV17 mitochondrial membrane protein-like 2 Mpv17l2 2.44 
NM_172116 Parkinson disease 7 domain containing 1 Pddc1 2.42 
NM_133719 meteorin, glial cell differentiation regulator Metrn 2.41 
NM_030694 interferon induced transmembrane protein 2 Ifitm2 2.38 
NM_145361 BTB (POZ) domain containing 2 Btbd2 2.37 
NM_009185 Scl/Tal1 interrupting locus Stil 2.37 
NM_016737 stress-induced phosphoprotein 1 Stip1 2.35 
NM_001163721 small integral membrane protein 1 , transcript variant 1 Smim1 2.35 
NM_032543 ring finger protein 123 Rnf123 2.35 
NM_018771 GIPC PDZ domain containing family, member 1 Gipc1 2.34 
NM_025378 interferon induced transmembrane protein 3 Ifitm3 2.32 
NM_029377 lin-37 homolog Lin37 2.30 
NM_001199337 apolipoprotein O, transcript variant 2 Apoo 2.29 
NM_133831 glioma tumor suppressor candidate region gene 2 Gltscr2 2.27 
NM_010219 FK506 binding protein 4 Fkbp4 2.27 
NM_138682 leucine rich repeat containing 4 Lrrc4 2.26 
NM_026457 spermatid associated, transcript variant 2 Spert 2.25 
NM_013515 stomatin Stom 2.24 
NM_053113 eosinophil-associated, ribonuclease A family, member 11 Ear11 2.21 
NM_177028 O-acyltransferase like Oacyl 2.18 
NM_011627 trophoblast glycoprotein, transcript variant 1 Tpbg 2.17 
NM_146244 ribosomal protein S6 kinase-like 1 Rps6kl1 2.16 
NM_133187 family with sequence similarity 198, member B Fam198b 2.14 
NM_001025610 
membrane-spanning 4-domains, subfamily A, member 7, 
transcript variant 2 Ms4a7 2.13 
NM_172488 laccase (multicopper oxidoreductase) domain containing 1 Lacc1 2.13 
NM_175118 dual specificity phosphatase 28 Dusp28 2.12 
NM_080595 EMI domain containing 1 Emid1 2.11 
NM_144556 leucine-rich repeat LGI family, member 4 Lgi4 2.11 
NM_019661 YKT6 homolog Ykt6 2.10 
NM_021294 diazepam binding inhibitor-like 5 Dbil5 2.09 
NM_016663 synaptotagmin III, transcript variant 1 Syt3 2.08 
NM_178919 lipase maturation factor 2 Lmf2 2.08 
NM_011073 perforin 1 (pore forming protein) Prf1 2.07 
NM_145390 
transportin 2 (importin 3, karyopherin beta 2b), transcript 
variant 1 Tnpo2 2.07 
NM_009538 pleiomorphic adenoma gene-like 1 Plagl1 2.05 
NM_026938 transmembrane protein 160 Tmem160 2.05 
NM_010129 epithelial membrane protein 3, transcript variant 1 Emp3 2.04 
NM_010590 ajuba LIM protein Ajuba 2.03 
NM_146156 PDLIM1 interacting kinase 1 like, transcript variant 1 Pdik1l 2.03 
NM_001195088 
transmembrane channel-like gene family 8, transcript variant 
A Tmc8 2.03 
NM_183194 gasdermin C3 Gsdmc3 2.01 
NM_027984 epsin 3 Epn3 2.00 
    
 Protein folding   
NM_024172 
HSPA (heat shock 70kDa) binding protein, cytoplasmic 
cochaperone 1 Hspbp1 2.47 
NM_175199 heat shock protein 12A Hspa12a 2.03 
    
 Proteolysis   
NM_023635 RAB27A, member RAS oncogene family Rab27a 5.79 
NM_009126 
serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), 
member 3A Serpinb3a 5.55 
NM_201363 serine (or cysteine) peptidase inhibitor, clade B, member 3C Serpinb3c 4.67 
NM_001169153 CD300 antigen like family member F, transcript variant 1 Cd300lf 4.17 
NM_145578 ubiquitin-conjugating enzyme E2M, transcript variant 1 Ube2m 3.50 
NM_025312 sclerostin domain containing 1* Sostdc1 4.30 
NM_025288 stefin A3 Stfa3 2.99 
NM_173869 stefin A2 like 1 Stfa2l1 2.98 
NM_001205070 Josephin domain containing 2, transcript variant 1 Josd2 2.94 
NM_175188 
membrane-associated ring finger (C3HC4) 1, transcript 
variant 3 March1 2.93 
NM_010767 mannan-binding lectin serine peptidase 2, transcript variant 2 Masp2 2.91 
NM_011187 proteasome (prosome, macropain) subunit, beta type 7 Psmb7 2.80 
NM_145420 ubiquitin-conjugating enzyme E2D 1 Ube2d1 2.74 
NM_008604 membrane metallo endopeptidase Mme 2.65 
NM_178738 protease, serine, 35 Prss35 2.60 
NM_007649 CD48 antigen Cd48 2.58 
NM_019461 ubiquitin specific peptidase 27, X chromosome Usp27x 2.53 
NM_198680 
serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), 
member 3B Serpinb3b 2.50 
NM_010612 kinase insert domain protein receptor Kdr 2.49 
NM_010418 
hect (homologous to the E6-AP (UBE3A) carboxyl terminus) 
domain and RCC1 (CHC1)-like domain (RLD) 2 Herc2 2.40 
NM_015783 ISG15 ubiquitin-like modifier Isg15 2.35 
NM_133354 SMT3 suppressor of mif two 3 homolog 2 Sumo2 2.26 
NM_011595 tissue inhibitor of metalloproteinase 3 Timp3 2.21 
NM_001001650 protease, serine, 48 Prss48 2.20 
NM_001082543 stefin A1 Stfa1 2.20 
NM_023386 receptor transporter protein Rtp4 2.15 
NM_198028 
serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), 
member 10, transcript variant 1 Serpinb10 2.09 
NM_008607 matrix metallopeptidase 13 Mmp13 2.09 
NM_173754 ubiquitin specific peptidase 43 Usp43 2.04 
NM_173052 serine (or cysteine) peptidase inhibitor, clade B, member 1b Serpinb1b 2.01 
    
 RNA processing   
NM_013932 DEAD (Asp-Glu-Ala-Asp) box polypeptide 25 Ddx25 12.54 
NM_012011 
eukaryotic translation initiation factor 2, subunit 3, structural 
gene Y-linked Eif2s3y 6.25 
NM_012008 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked Ddx3y 5.02 
NM_153416 achalasia, adrenocortical insufficiency, alacrimia Aaas 3.31 
NM_011358 serine/arginine-rich splicing factor 2 Srsf2 2.99 
NM_025500 mitochondrial ribosomal protein L37 Mrpl37 2.94 
NM_018799 eukaryotic translation initiation factor 3, subunit I Eif3i 2.70 
NM_001008422 SR-related CTD-associated factor 1 Scaf1 2.54 
NM_011431 
elongation factor Tu GTP binding domain containing 2, 
transcript variant 1 Eftud2 2.42 
NM_001166589 eukaryotic translation initiation factor 5A, transcript variant 1 Eif5a 2.41 
NM_175001 mitochondrial ribosomal protein L22 Mrpl22 2.35 
NM_026080 mitochondrial ribosomal protein S24 Mrps24 2.32 
NM_023133 ribosomal protein S19 Rps19 2.26 
NM_016805 heterogeneous nuclear ribonucleoprotein U Hnrnpu 2.24 
NM_175235 CUGBP, Elav-like family member 6 Celf6 2.22 
NM_177367 gem (nuclear organelle) associated protein 4 Gemin4 2.20 
NM_173757 mitochondrial ribosomal protein S27 Mrps27 2.19 
NM_019484 Aly/REF export factor 2 Alyref2 2.15 
NM_148917 poly(A) binding protein, cytoplasmic 4, transcript variant 2 Pabpc4 2.14 
NM_009070 ribonucleic acid binding protein S1, transcript variant 1 Rnps1 2.12 
NM_207523 ribosomal protein L23A Rpl23a 2.12 
NM_021288 thymidylate synthase, transcript variant 1 Tyms 2.09 
NM_022313 Era (G-protein)-like 1 Eral1 2.08 
NM_013507 
eukaryotic translation initiation factor 4, gamma 2, transcript 
variant 1 Eif4g2 2.01 
    
 Signalling   
NM_010100 ectodysplasin-A receptor* Edar 58.69 
NM_009170 sonic hedgehog* Shh 45.41 
NM_176996 smoothened homolog (Drosophila) (Smo) Smo 36.25 
NM_008958 patched homolog 2 Ptch2 25.72 
NM_133249 peroxisome proliferative activated receptor, gamma, Ppargc1b 16.21 
coactivator 1 beta 
NM_009987 chemokine (C-X3-C) receptor 1 Cx3cr1 9.75 
ENSMUST00000
029611 lymphoid enhancer binding factor 1* Lef1 9.68 
NM_001033960 RAB GTPase activating protein 1, transcript variant 2 Rabgap1 8.53 
NM_007416 adrenergic receptor, alpha 1b Adra1b 6.07 
NM_001042605 CD74 antigen, transcript variant 1 Cd74 5.86 
NM_199022 SHC (Src homology 2 domain containing) family, member 4 Shc4 4.08 
NM_026864 RAS-like, family 11, member A Rasl11a 3.99 
NM_001272024 sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6C , transcript variant 1 Sema6c 3.85 
NM_009835 chemokine (C-C motif) receptor 6, transcript variant 1 Ccr6 3.73 
NM_146862 olfactory receptor 763 Olfr763 3.59 
NM_001081105 ras homolog gene family, member H Rhoh 3.57 
NM_022324 stromal cell-derived factor 2-like 1 Sdf2l1 3.57 
NM_008973 pleiotrophin Ptn 3.52 
NM_011562 teratocarcinoma-derived growth factor 1 Tdgf1 3.47 
NM_027242 protein phosphatase 1, regulatory subunit 35 Ppp1r35 3.44 
NM_013834 secreted frizzled-related protein 1 Sfrp1 3.36 
NM_146457 olfactory receptor 282 Olfr282 3.04 
NM_011428 synaptosomal-associated protein 25 Snap25 2.85 
NM_028808 purinergic receptor P2Y, G-protein coupled 13 P2ry13 2.84 
NM_021885 tubby candidate gene Tub 2.75 
NM_007889 dishevelled 3, dsh homolog Dvl3 2.71 
NM_010275 glial cell line derived neurotrophic factor Gdnf 2.68 
NM_008975 protein tyrosine phosphatase 4a3, transcript variant 2 Ptp4a3 2.64 
NM_008086 growth arrest specific 1 Gas1 2.61 
NM_029408 IQ motif containing D Iqcd 2.61 
NM_183315 cortexin 1 Ctxn1 2.6 
NM_207666 delta-like 2 homolog Dlk2 2.6 
NM_010733 leucine rich repeat protein 3, neuronal, transcript variant 2 Lrrn3 2.58 
NM_029057 TBC1 domain family, member 30 Tbc1d30 2.58 
NM_177740 RGM domain family, member A Rgma 2.58 
NM_013739 docking protein 3 Dok3 2.54 
NM_010517 insulin-like growth factor binding protein 4 Igfbp4 2.52 
NM_007479 ADP-ribosylation factor 4 Arf4 2.51 
NM_009708 Rho family GTPase 2 Rnd2 2.48 
NM_008342 insulin-like growth factor binding protein 2 Igfbp2 2.48 
NM_022657 fibroblast growth factor 23 Fgf23 2.46 
NM_028804 coiled-coil domain containing 3 Ccdc3 2.44 
NM_026814 protein phosphatase 1, regulatory subunit 27 Ppp1r27 2.43 
NM_198249 Rho guanine nucleotide exchange factor (GEF) 40 , transcript variant 1 Arhgef40 2.43 
NM_008356 interleukin 13 receptor, alpha 2 Il13ra2 2.41 
NM_011823 G protein-coupled receptor 34 Gpr34 2.41 
NM_010572 insulin receptor substrate 4 Irs4 2.38 
NM_145431 notchless homolog 1 Nle1 2.38 
NM_145373 secreted and transmembrane 1A Sectm1a 2.37 
NM_027280 naked cuticle 1 homolog, transcript variant 1 Nkd1 2.37 
NM_026840 platelet-derived growth factor receptor-like Pdgfrl 2.34 
NM_007955 protein tyrosine phosphatase, receptor type, V Ptprv 2.31 
NM_009750 nerve growth factor receptor (TNFRSF16) associated protein 1, transcript variant 1 Ngfrap1 2.26 
NM_145379 MAS-related GPR, member F Mrgprf 2.26 
NM_016719 growth factor receptor bound protein 14 Grb14 2.25 
NM_016802 ras homolog gene family, member A Rhoa 2.25 
NM_001033484 IQ motif containing GTPase activating protein 3 Iqgap3 2.25 
NM_009109 ryanodine receptor 1, skeletal muscle Ryr1 2.22 
NM_008865 prolactin family 3, subfamily b, member 1 Prl3b1 2.22 
NM_146216 Vac14 homolog Vac14 2.22 
NM_009314 tachykinin receptor 2 Tacr2 2.21 
NM_016891 protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoform Ppp2r1a 2.21 
NM_016971 interleukin 22 Il22 2.2 
NM_007486 Rho, GDP dissociation inhibitor (GDI) beta (Arhgdib) Arhgdib 2.19 
NM_021476 cysteinyl leukotriene receptor 1 Cysltr1 2.18 
NM_011915 Wnt inhibitory factor 1 Wif1 2.18 
NM_009216 somatostatin receptor 1 Sstr1 2.18 
NM_001011850 olfactory receptor 1505 Olfr1505 2.17 
NM_147030 olfactory receptor 1134 Olfr1134 2.14 
NM_009028 RAS-like, family 2, locus 9 Rasl2-9 2.13 
NM_026446 regulator of G-protein signaling 19 Rgs19 2.13 
NM_010273 guanosine diphosphate (GDP) dissociation inhibitor 1 Gdi1 2.11 
NM_146356 olfactory receptor 521 Olfr521 2.11 
NM_020257 C-type lectin domain family 2, member i Clec2i 2.1 
NM_138748 protein phosphatase 2A, regulatory subunit B (PR 53) Ppp2r4 2.09 
NM_206975 interferon, alpha 14 Ifna14 2.08 
NM_023209 PDZ binding kinase Pbk 2.06 
NM_008728 natriuretic peptide receptor 3 Npr3 2.04 
NM_007865 delta-like 1 Dll1 2.04 
NM_017472 sorting nexin 3 Snx3 2.03 
NM_001198766 periostin, osteoblast specific factor, transcript variant 3 Postn 2.02 
NM_031875 otoferlin, transcript variant 2 Otof 2.02 
NM_175168 PTK7 protein tyrosine kinase 7 Ptk7 2.02 
NM_028416 kringle containing transmembrane protein 2 Kremen2 2.02 
NM_020259 Hedgehog-interacting protein Hhip 2.01 
NM_008113 Rho GDP dissociation inhibitor (GDI) gamma Arhgdig 2.01 
NM_001033851 copine VIII, transcript variant 2 Cpne8 2 
NM_001038018 G protein-coupled receptor kinase 6, transcript variant 1 Grk6 2 
NM_029646 interleukin 34, transcript variant 2 Il34 2 
NM_001164724 interleukin 33, transcript variant 1 Il33 2 
NM_001110320 CD72 antigen, transcript variant 1 Cd72 1.99 
NM_027571 purinergic receptor P2Y, G-protein coupled 12 P2ry12 1.99 
NM_001165902 beta-catenin* Ctnnb1 1.4 
 Transcription   
NM_172495 nuclear receptor coactivator 7, transcript variant 1 Ncoa7 11.61 
NM_027395 brain abundant, membrane attached signal protein 1 Basp1 4.75 
NM_011640 transformation related protein 53, transcript variant 1 Trp53 3.77 
NM_008709 
v-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived Mycn 3.65 
NM_008688 nuclear factor I/C, transcript variant 1 Nfic 3.56 
NM_009236 SRY-box containing gene 18 Sox18 3.55 
NM_181319 T-box 22, transcript variant 2 Tbx22 3.54 
NM_016662 Max dimerization protein 3 Mxd3 3.37 
NM_010055 distal-less homeobox 3 Dlx3 3.30 
NM_025788 
nucleus accumbens associated 1, BEN and BTB (POZ) 
domain containing Nacc1 3.02 
NM_028016 Nanog homeobox Nanog 2.94 
NM_010466 homeobox C8 Hoxc8 2.87 
NM_009089 polymerase (RNA) II (DNA directed) polypeptide A Polr2a 2.81 
NM_009331 transcription factor 7, T cell specific Tcf7 2.76 
NM_170759 zinc finger protein 628 (Zfp628) Zfp628 2.73 
NM_178757 interferon regulatory factor 2 binding protein 1 Irf2bp1 2.68 
NM_026776 vacuolar protein sorting 25 Vps25 2.65 
NM_026532 nuclear transport factor 2 Nutf2 2.64 
NM_009235 SRY-box containing gene 15 Sox15 2.62 
NM_146040 cell division cycle associated 7 like Cdca7l 2.62 
NM_008505 LIM domain only 2, transcript variant 1 Lmo2 2.58 
NM_001037914 multiciliate cell differentiation Mcin 2.50 
NM_026192 calcium binding and coiled coil domain 1 Calcoco1 2.49 
NM_011642 transformation related protein 73, transcript variant 1 Trp73 2.46 
NM_001001980 LIM and calponin homology domains 1, transcript variant 1 Limch1 2.39 
NM_010919 NK2 transcription factor related, locus 2, transcript variant 1 Nkx2-2 2.37 
NM_178609 E2F transcription factor 7 E2f7 2.37 
NM_027946 DDB1 and CUL4 associated factor 7 Dcaf7 2.36 
NM_001033813 zinc finger protein 872 Zfp872 2.35 
NM_011139 POU domain, class 2, transcription factor 3 Pou2f3 2.34 
NM_011869 mediator complex subunit 24 Med24 2.33 
NM_010835 homeobox, msh-like 1 Msx1 2.32 
NM_008269 homeobox B6 Hoxb6 2.24 
NM_026937 
activating signal cointegrator 1 complex subunit 1 ,  transcript 
variant 2 Ascc1 2.23 
NM_019574 
POZ (BTB) and AT hook containing zinc finger 1, transcript 
variant 1 Patz1 2.22 
NM_001109743 SKI family transcriptional corepressor 2 Skor2 2.22 
NM_021501 protein inhibitor of activated STAT 4 Pias4 2.22 
NM_001163763 transcription factor 19, transcript variant 1 Tcf19 2.21 
NM_027658 
hexamethylene bis-acetamide inducible 2 , 
transcript variant 1 Hexim2 2.17 
NM_001034900 zinc finger protein 345 Zfp345 2.15 
NM_019776 staphylococcal nuclease and tudor domain containing 1 Snd1 2.12 
NM_029281 zinc finger protein 820 Zfp820 2.11 
NM_008627 Meis homeobox 3 Meis3 2.09 
NM_001168502 zinc finger protein 57, transcript variant 3 Zfp57 2.08 
NM_194350 
v-maf musculoaponeurotic fibrosarcoma oncogene family, 
protein A Mafa 2.06 
NM_145836 interferon regulatory factor 2 binding protein-like Irf2bpl 2.06 
NM_011249 retinoblastoma-like 1 (p107), transcript variant 1 Rbl1 2.06 
NM_011377 single-minded homolog 2 Sim2 2.04 
NM_025945 
polymerase (RNA) III (DNA directed) polypeptide D, 
transcript variant 1 Polr3d 2.04 
NM_027434 regulation of nuclear pre-mRNA domain containing 1B Rprd1b 2.04 
NM_008321 inhibitor of DNA binding 3 Id3 2.02 
NM_010464 homeobox C13 Hoxc13 2.02 
NM_009056 
regulatory factor X, 2 (influences HLA class II expression), 
transcript variant 2 Rfx2 2.01 
NM_001013368 E2F transcription factor 8 E2f8 2.01 
NM_144799 LIM and cysteine-rich domains 1 Lmcd1 2.00 
NM_022435 trans-acting transcription factor 5 Sp5 2.00 
NM_008500 LIM homeobox protein 6, transcript variant 1 Lhx6 1.99 
NM_007531 prohibitin 2 Phb2 1.99 
    
 Transport   
NM_012037 vesicle amine transport protein 1 homolog Vat1 2.04 
NM_001164679 anoctamin 8 Ano8 2.23 
NM_008226 hyperpolarization-activated, cyclic nucleotide-gated K+ 2 Hcn2 3.05 
 
 
*genes validated by qPCR 
 
Table S2. Genes that show 2-fold up-regulation in the epithelium of K14rtTA/TRE-
miR-214 mice versus WT mice 
 
Accession 
Number Gene Name Symbol Fold Change 
    
 Adhesion/Extracellular matrix   
NM_018857 mesothelin  Msln 43.81 
NM_009856 CD83 antigen Cd83 3.46 
NM_139200 cytohesin 1 interacting protein Cytip 3.39 
NM_027852 retinoic acid receptor responder (tazarotene induced) 2  Rarres2 3.08 
NM_001243008 collagen, type VI, alpha 3, transcript variant 1 Col6a3 2.98 
NM_009903 claudin 4  Cldn4 2.96 
NM_022032 PERP, TP53 apoptosis effector  Perp 2.76 
NM_001008424 corneodesmosin Cdsn 2.67 
NM_010516 cysteine rich protein 61 Cyr61 2.56 
NM_008013 fibrinogen-like protein 2  Fgl2 2.5 
NM_053146 protocadherin beta 21  Pcdhb21 2.37 
NM_021893 CD274 antigen  Cd274 2.31 
NM_138672 stabilin 1  Stab1 2.3 
NM_145158 elastin microfibril interfacer 2  Emilin2 2.25 
NM_001093749 myelin protein zero-like 3, transcript variant 2 Mpzl3 2.19 
NM_027893 poliovirus receptor-related 4 , transcript variant 1 Pvrl4 2.19 
NM_033620 par-3 (partitioning defective 3) homolog, transcript variant 3 Pard3 2.18 
NM_016919 collagen, type V, alpha 3  Col5a3 2.17 
NM_010814 myelin oligodendrocyte glycoprotein Mog 2.17 
NM_008127 gap junction protein, beta 4 Gjb4 2.16 
NM_010291 gap junction protein, beta 5  Gjb5 2.16 
NM_011016 orosomucoid 2  Orm2 2.16 
NM_001111058 CD33 antigen, transcript variant 1 Cd33 2.15 
NM_080437 
cadherin, EGF LAG seven-pass G-type receptor 3 
(flamingo homolog, Drosophila)  Celsr3 2.13 
NM_133743 Ly6/Plaur domain containing 3 Lypd3 2.13 
NM_001113368 
carcinoembryonic antigen-related cell adhesion molecule 2, 
transcript variant 1 Ceacam2 2.1 
NM_008768 orosomucoid 1  Orm1 2.09 
NM_028523 discoidin, CUB and LCCL domain containing 2  Dcbld2 2.08 
NM_007993 fibrillin 1  Fbn1 2.08 
NM_023420 
collagen, type IV, alpha 3 binding protein, transcript variant 
1 Col4a3bp 2.05 
NM_001081053 integrin, alpha 10  Itga10 2 
    
 Cell Cycle/Apoptosis   
NM_009397 
tumor necrosis factor, alpha-induced protein 3, transcript 
variant 1 Tnfaip3 5.11 
NM_007570 B cell translocation gene 2, anti-proliferative Btg2 4.69 
NM_011540 titin-cap  Tcap 4.31 
NM_013642 dual specificity phosphatase 1  Dusp1 3.28 
NM_207677 death effector domain-containing DNA binding protein 2 Dedd2 2.96 
NM_009871 cyclin-dependent kinase 5, regulatory subunit 1 (p35)  Cdk5r1 2.63 
NM_001162908 sestrin 1, transcript variant 1 Sesn1 2.61 
NM_001081156 TMF1-regulated nuclear protein 1  Trnp1 2.61 
NM_130886 caspase recruitment domain family, member 14 Card14 2.59 
NM_009760 BCL2/adenovirus E1B interacting protein 3 Bnip3 2.46 
NM_007609 caspase 4, apoptosis-related cysteine peptidase Casp4 2.42 
NM_008681 N-myc downstream regulated gene 1  Ndrg1 2.32 
NM_013469 annexin A11 Anxa11 2.25 
NM_025427 regulator of cell cycle  Rgcc 2.17 
NM_001103182 lin-9 homolog, transcript variant 1 Lin9 2.14 
NM_144899 ADAMTS-like 4 Adamtsl4 2.13 
NM_001003920 BR serine/threonine kinase 1, transcript variant 1 Brsk1 2 
NM_008795 cyclin-dependent kinase 18  Cdk18 2 
    
 Chromatin remodeling   
NM_001097979 histone cluster 1, H2bq  Hist1h2bq 59.61 
NM_178909 WD repeat domain 92 Wdr92 9.88 
NM_178196 histone cluster 1, H2bg  Hist1h2bg 5.99 
NM_015786 histone cluster 1, H1c  Hist1h1c 4.74 
NM_023422 histone cluster 1, H2bc Hist1h2bc 4.26 
BC015270 histone cluster 2, H3c2 Hist2h3c2 3.7 
BC059807 chromodomain helicase DNA binding protein 6 Chd6 3.64 
NM_199299 PHD finger protein 15  Phf15 3.61 
NM_013807 polo-like kinase 3  Plk3 3.51 
NM_025519 charged multivesicular body protein 4C  Chmp4c 3.27 
NM_001167884 
suppressor of variegation 4-20 homolog 1 (Drosophila) , 
transcript variant 7 Suv420h1 2.69 
NM_030082 histone cluster 3, H2ba  Hist3h2ba 2.58 
NM_001081315 bromodomain and PHD finger containing, 3 Brpf3 2.49 
NM_178218 histone cluster 3, H2a  Hist3h2a 2.4 
NM_001109691 PHD finger protein 21A, transcript variant 3 Phf21a 2.34 
NM_001128151 cat eye syndrome chromosome region, candidate 2  Cecr2 2.33 
NM_001081269 
Wolf-Hirschhorn syndrome candidate 1-like 1, transcript 
variant 2 Whsc1l1 2.24 
NM_153421 polyhomeotic-like 3 (Drosophila) , transcript variant 2 Phc3 2.22 
NM_010434 
homeodomain interacting protein kinase 3, transcript 
variant 1 Hipk3 2.19 
NM_027892 protein phosphatase 1, regulatory (inhibitor) subunit 12A  Ppp1r12a 2.16 
NM_026110 PAX3 and PAX7 binding protein 1  Paxbp1 2.14 
NM_001017426 KDM1 lysine (K)-specific demethylase 6B Kdm6b 2.04 
NM_001177374 
ubiquitin protein ligase E3 component n-recognin 2, 
transcript variant 2 Ubr2 2.03 
NM_011235 RAD51 homolog D  Rad51d 2.02 
    
 Cytoskeleton   
NM_008508 loricrin  Lor 8.18 
NM_025420 late cornified envelope 1M  Lce1m 5.51 
NM_027762 trichohyalin-like 1  Tchhl1 4.5 
NM_001099774 keratin associated protein 17-1 Krtap17-1 3.85 
NM_029667 late cornified envelope 1I Lce1i 3.83 
NM_212487 keratin 78 Krt78 3.81 
NM_027137 late cornified envelope 1D Lce1d 3.62 
NM_011472 small proline-rich protein 2F  Sprr2f 3.61 
NM_001005510 spectrin repeat containing, nuclear envelope 2  Syne2 3.5 
NM_013560 heat shock protein 1 Hspb1 3.49 
NM_026394 late cornified envelope 1F Lce1f 3.49 
NM_011470 small proline-rich protein 2D  Sprr2d 3.49 
NM_033373 keratin 23 Krt23 3.38 
NM_011471 small proline-rich protein 2E  Sprr2e 3.23 
NM_011619 troponin T2, cardiac, transcript variant 9 Tnnt2 3.19 
NM_010664 keratin 18 Krt18 3.14 
NM_001252372 myosin binding protein C, slow-type , transcript variant 1 Mybpc1 3.14 
NM_008473 keratin 1 Krt1 3.06 
NM_028622 late cornified envelope 1C (Lce1c) Lce1c 2.97 
NM_001039376 
phosphodiesterase 4D interacting protein (myomegalin), 
transcript variant 1 Pde4dip 2.88 
NM_026822 late cornified envelope 1B Lce1b 2.84 
NM_001271484 
CAP-GLY domain containing linker protein family, member 
4, transcript variant 4 Clip4 2.79 
NM_028044 calponin 3, acidic Cnn3 2.75 
NM_007585 annexin A2 Anxa2 2.74 
NM_033175 late cornified envelope 3C  Lce3c 2.72 
NM_025501 late cornified envelope 3B Lce3b 2.64 
NM_001018079 late cornified envelope 3F Lce3f 2.59 
NM_026811 late cornified envelope 1E Lce1e 2.57 
NM_001270426 late cornified envelope 3D Lce3d 2.55 
NM_001039472 kinesin family member 21B Kif21b 2.4 
NM_018790 activity regulated cytoskeletal-associated protein Arc 2.38 
NM_028721 nephronophthisis 3 (adolescent), transcript variant 1 Nphp3 2.38 
NM_025413 late cornified envelope 1G Lce1g 2.33 
NM_030203 TSPY-like 4  Tspyl4 2.33 
NM_145070 huntingtin interacting protein 1 related Hip1r 2.26 
NM_010630 kinesin family member C2 Kifc2 2.24 
NM_025984 late cornified envelope 1A1 Lce1a1 2.24 
NM_019765 CAP-GLY domain containing linker protein 1 Clip1 2.19 
NM_001039594 late cornified envelope 3A Lce3a 2.18 
NM_146120 gelsolin, transcript variant 1 Gsn 2.17 
NM_001109657 growth arrest specific 7, transcript variant 2 Gas7 2.14 
NM_133357 keratin 75  Krt75 2.11 
NM_001254760 late cornified envelope 1K  Lce1k 2.11 
NM_019809 PDZ and LIM domain 5, transcript variant 2 Pdlim5 2.08 
NM_009450 tubulin, beta 2A class IIA  Tubb2a 2.07 
NM_010660 keratin 10 Krt10 2.06 
NM_175180 WD repeat domain 44 Wdr44 2.06 
NM_178593 RCSD domain containing 1, transcript variant 1 Rcsd1 2.04 
NM_198113 slingshot homolog 3  Ssh3 2.03 
NM_001163664 troponin T3, skeletal, fast , transcript variant 1 Tnnt3 2.01 
    
 Metabolism   
NM_013743 
pyruvate dehydrogenase kinase, isoenzyme 4, nuclear 
gene encoding mitochondrial protein Pdk4 5.79 
NM_175650 ATPase type 13A5 Atp13a5 5.26 
NM_027299 
degenerative spermatocyte homolog 2 (Drosophila), lipid 
desaturase, transcript variant 1 Degs2 5.02 
NM_011435 superoxide dismutase 3, extracellular  Sod3 4.95 
NM_146118 
solute carrier family 25 (mitochondrial carrier, phosphate 
carrier), member 25, transcript variant 1 Slc25a25 4.52 
NM_001111331 
Kv channel interacting protein 3, calsenilin , transcript 
variant 2 Kcnip3 4.38 
NM_001199283 solute carrier family 43, member 2, transcript variant 1 Slc43a2 4.33 
NM_007409 alcohol dehydrogenase 1 (class I)  Adh1 4.23 
NM_001164613 ATPase type 13A4, transcript variant 3 Atp13a4 4.18 
NM_001130194 bestrophin 2, transcript variant 1 Best2 4.18 
NM_009593 ATP-binding cassette, sub-family G (WHITE), member 1 Abcg1 3.91 
NM_026945 alcohol dehydrogenase 6A (class V) Adh6a 3.68 
NM_001177753 
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, 
transcript variant 2 Pfkfb3 3.61 
NM_194333 
solute carrier family 23 (nucleobase transporters), member 
3  Slc23a3 3.52 
NM_001098789 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, Ndufa4l2 3.45 
4-like 2  
NM_011031 
procollagen-proline, 2-oxoglutarate 4-dioxygenase, alpha II 
polypeptide , transcript variant 2 P4ha2 3.45 
NM_030696 
solute carrier family 16 (monocarboxylic acid transporters), 
member 3 Slc16a3 3.28 
NM_001042591 arrestin domain containing 3 Arrdc3 3.27 
NM_028784 coagulation factor XIII, A1 subunit, transcript variant 1 F13a1 3.24 
NM_028133 EGL nine homolog 3 (C. elegans)  Egln3 3.13 
NM_183161 solute carrier family 17, member 9 Slc17a9 3.01 
NM_033648 
FXYD domain-containing ion transport regulator 4, 
transcript variant 1 Fxyd4 2.99 
NM_001111111 autophagy related 16-like 2  Atg16l2 2.92 
NM_001114084 diacylglycerol O-acyltransferase 2-like 6  Dgat2l6 2.88 
NM_029415 
solute carrier family 10 (sodium/bile acid cotransporter 
family), member 6  Slc10a6 2.84 
NM_007421 adenylosuccinate synthetase like 1 Adssl1 2.74 
NM_172883 major facilitator superfamily domain containing 7A Mfsd7a 2.74 
NM_013455 acrosin prepropeptide, transcript variant 1 Acr 2.71 
NM_172837 lipase, family member K, transcript variant 2 Lipk 2.7 
NM_030558 carbonic anhydrase 15  Car15 2.68 
NM_153143 potassium channel tetramerisation domain containing 11  Kctd11 2.67 
NM_001267707 
solute carrier organic anion transporter family, member 
1a5, transcript variant 1 Slco1a5 2.67 
NM_007470 apolipoprotein D Apod 2.66 
NM_001195033 abhydrolase domain containing 12B  Abhd12b 2.65 
NM_001079865 carboxylesterase 2F Ces2f 2.65 
NM_011198 prostaglandin-endoperoxide synthase 2  Ptgs2 2.65 
NM_172524 NIPA-like domain containing 4  Nipal4 2.63 
NM_177243 solute carrier family 26, member 9  Slc26a9 2.62 
NM_153404 lipase, member H, transcript variant 2 Liph 2.58 
NM_019664 
potassium inwardly-rectifying channel, subfamily J, 
member 15 , transcript variant 2 Kcnj15 2.57 
NM_001160165 neuraminidase 2, transcript variant 3 Neu2 2.56 
NM_009695 apolipoprotein C-II  Apoc2 2.55 
NM_011786 arachidonate lipoxygenase 3  Aloxe3 2.53 
NM_001039176 
elongation of very long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 1, transcript variant 1 Elovl1 2.49 
NM_175475 
cytochrome P450, family 26, subfamily b, polypeptide 1, 
transcript variant 1 Cyp26b1 2.46 
NM_001081349 solute carrier family 43, member 1, transcript variant 1 Slc43a1 2.41 
NM_134006 retinol dehydrogenase 5  Rdh5 2.4 
NM_001012434 
potassium channel tetramerisation domain containing 14, 
transcript variant 2 Kctd14 2.39 
NM_029688 sulfiredoxin 1 homolog  Srxn1 2.39 
NM_001042719 DDHD domain containing 1, transcript variant 3 Ddhd1 2.36 
NM_001081421 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 1 Galntl1 2.36 
NM_173785 
IBA57, iron-sulfur cluster assembly homolog, transcript 
variant 1 Iba57 2.35 
NM_027172 
solute carrier protein family 52, member 3 ,  transcript 
variant 1 Slc52a3 2.35 
NM_009022 aldehyde dehydrogenase family 1, subfamily A2  Aldh1a2 2.32 
NM_027868 solute carrier family 41, member 3, transcript variant 1 Slc41a3 2.32 
NM_145828 xylosyltransferase II  Xylt2 2.32 
NM_021301 
solute carrier family 15 (H+/peptide transporter), member 2, 
transcript variant 1 Slc15a2 2.28 
BC047268 phospholipase D2 Pld2 2.27 
NM_183220 
1-aminocyclopropane-1-carboxylate synthase (non-
functional) Accs 2.24 
NM_172692 glucosidase beta 2  Gba2 2.23 
NM_053079 
solute carrier family 15 (oligopeptide transporter), member 
1 Slc15a1 2.23 
NM_018830 N-acylsphingosine amidohydrolase 2 Asah2 2.22 
NM_018881 flavin containing monooxygenase 2  Fmo2 2.22 
NM_013509 enolase 2, gamma neuronal  Eno2 2.21 
NM_001163689 
patatin-like phospholipase domain containing 2, transcript 
variant 1 Pnpla2 2.21 
NM_026784 phosphomevalonate kinase, transcript variant 1 Pmvk 2.18 
NM_026644 
1-acylglycerol-3-phosphate O-acyltransferase 4 
(lysophosphatidic acid acyltransferase, delta)  Agpat4 2.17 
NM_010239 ferritin heavy chain 1, transcript variant 1 Fth1 2.17 
NM_008504 granzyme M (lymphocyte met-ase 1) Gzmm 2.17 
NM_145423 solute carrier family 5 (iodide transporter), member 8 Slc5a8 2.17 
NM_052993 
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-
beta-galactosyltransferase, 1  C1galt1 2.16 
NM_019779 cytochrome P450, family 11, subfamily a, polypeptide 1  Cyp11a1 2.16 
NM_175331 5'-nucleotidase domain containing 3  Nt5dc3 2.16 
NM_008131 glutamate-ammonia ligase (glutamine synthetase)  Glul 2.15 
NM_009177 ST3 beta-galactoside alpha-2,3-sialyltransferase 1  St3gal1 2.15 
NM_001039710 coenzyme Q10 homolog B, transcript variant 1 Coq10b 2.14 
NM_027340 lipase, family member N Lipn 2.13 
NM_147219 ATP-binding cassette, sub-family A , member 5 Abca5 2.09 
NM_019807 acid phosphatase, prostate , transcript variant 2 Acpp 2.07 
NM_172607 nicotinate phosphoribosyltransferase domain containing 1 Naprt1 2.07 
NM_029810 5'-nucleotidase, cytosolic II , transcript variant 3 Nt5c2 2.07 
NM_027406 aldehyde dehydrogenase 1 family, member L1  Aldh1l1 2.06 
NM_153803 galactosidase, beta 1-like 2  Glb1l2 2.06 
NM_001159864 
potassium channel tetramerisation domain containing 18, 
transcript variant 1 Kctd18 2.05 
NM_001161767 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 6, transcript variant 1 Galnt6 2.04 
NM_145447 major facilitator superfamily domain containing 7C Mfsd7c 2.04 
NM_013820 hexokinase 2  Hk2 2.03 
NM_001161765 flavin containing monooxygenase 5, transcript variant 1 Fmo5 2.02 
NM_025718 deoxyribonuclease 1-like 2  Dnase1l2 2.02 
NM_013850 ATP-binding cassette, sub-family A, member 7  Abca7 2.01 
NM_009721 ATPase, Na+/K+ transporting, beta 1 polypeptide Atp1b1 2.01 
    
 Others   
NM_172051 
transmembrane and coiled coil domains 3, transcript 
variant 1 Tmcc3 7.29 
NM_001163502 
ELM2 and Myb/SANT-like domain containing 1, transcript 
variant 1 Elmsan1 6.84 
NM_001166173 dermokine, transcript variant 3 Dmkn 5.26 
NM_001204959 resistin , transcript variant 2 Retn 5.11 
NM_175307 family with sequence similarity 46, member B  Fam46b 4.69 
NM_001199210 eva-1 homolog C (C. elegans) , transcript variant 1 Eva1c 4.66 
NM_197986 transmembrane protein 140  Tmem140 4 
NM_172205 suprabasin, transcript variant 1 Sbsn 3.93 
NM_001190436 
Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) 
ubiquitously expressed, transcript variant 3 Fau 3.74 
NM_028798 cysteine-rich C-terminal 1 Crct1 3.73 
NM_001033411 predicted gene 826  Gm826 3.55 
BC090258 interferon induced transmembrane protein 1 Ifitm1 3.24 
NM_027511 histidine rich carboxyl terminus 1  Hrct1 3.19 
NM_013473 annexin A8 Anxa8 3.16 
NM_009778 complement component 3 C3 3.16 
NM_145535 syndecan binding protein (syntenin) 2  Sdcbp2 2.91 
NM_027585 cyclic nucleotide binding domain containing 2 Cnbd2 2.88 
NM_001013749 transmembrane protein 151B  Tmem151b 2.87 
NM_172801 otopetrin 2  Otop2 2.85 
NM_001033410 predicted gene 757 Gm757 2.79 
NM_181397 raftlin lipid raft linker 1  Rftn1 2.78 
NM_001163572 transmembrane protein 170B  Tmem170b 2.73 
NM_001025572 ankyrin repeat domain 12 Ankrd12 2.58 
NM_010220 FK506 binding protein 5  Fkbp5 2.57 
NM_173415 nyctalopin  Nyx 2.57 
NM_175407 sine oculis-binding protein homolog (Drosophila)  Sobp 2.56 
NM_176860 ubiquitin associated and SH3 domain containing, B Ubash3b 2.56 
NM_010732 leucine rich repeat protein 2, neuronal Lrrn2 2.52 
NM_031195 macrophage scavenger receptor 1, transcript variant 1 Msr1 2.52 
NM_020578 EH-domain containing 3  Ehd3 2.48 
NM_011573 testis expressed gene 264, transcript variant 1 Tex264 2.48 
NM_013562 interferon-related developmental regulator 1 Ifrd1 2.4 
NM_019576 thrombospondin, type I, domain 1, transcript variant 1 Thsd1 2.39 
NM_170684 copine VII  Cpne7 2.38 
NM_029116 kelch repeat and BTB (POZ) domain containing 11 Kbtbd11 2.38 
NM_010706 lectin, galactose binding, soluble 4  Lgals4 2.37 
NM_176834 ring finger protein 208  Rnf208 2.37 
NM_011029 ribosomal protein SA  Rpsa 2.36 
NM_026146 EPS8-like 1 Eps8l1 2.34 
NM_178884 obscurin-like 1  Obsl1 2.33 
NM_146008 t-complex 11 (mouse) like 2  Tcp11l2 2.32 
NM_026835 membrane-spanning 4-domains, subfamily A, member 6D Ms4a6d 2.31 
NM_001085507 zinc finger and BTB domain containing 34  Zbtb34 2.31 
NM_133898 NEDD4 binding protein 2-like 1  N4bp2l1 2.3 
NM_001081652 NAC alpha domain containing Nacad 2.3 
NM_001162974 leucine rich repeat containing 51, transcript variant 3 Lrrc51 2.29 
NM_001038592 glutaredoxin 2 , transcript variant 1 Glrx2 2.28 
NM_001205353 GRAM domain containing 4, transcript variant 2 Gramd4 2.28 
NM_144797 meteorin, glial cell differentiation regulator-like  Metrnl 2.28 
NM_001159577 ligand of numb-protein X 1, transcript variant 1 Lnx1 2.24 
NM_027898 GRAM domain containing 1A Gramd1a 2.23 
NM_001136259 target of myb1 homolog, transcript variant 2 Tom1 2.22 
NM_009150 selenium binding protein 1 Selenbp1 2.2 
NM_001164557 PDZK1 interacting protein 1 , transcript variant 1 Pdzk1ip1 2.18 
NM_145853 two pore channel 1  Tpcn1 2.17 
NM_053167 tripartite motif-containing 9 , transcript variant 1 Trim9 2.17 
NM_027166 yippee-like 5 Ypel5 2.17 
NM_011157 serglycin  Srgn 2.16 
NM_026588 syntaxin 19  Stx19 2.16 
NM_001168514 mitogen-activated protein kinase 14, transcript variant 4 Mapk14 2.15 
NM_178242 trinucleotide repeat containing 18, transcript variant B Tnrc18 2.14 
NM_009441 tetratricopeptide repeat domain 3  Ttc3 2.14 
NM_153507 copine II Cpne2 2.13 
NM_013532 
leukocyte immunoglobulin-like receptor, subfamily B, 
member 4 Lilrb4 2.13 
NM_001081235 meningioma 1  Mn1 2.13 
NM_001024134 tripartite motif-containing 15, transcript variant 2 Trim15 2.13 
NM_011123 proteolipid protein (myelin) 1  Plp1 2.12 
NM_053166 tripartite motif-containing 7  Trim7 2.12 
NM_181073 
pleckstrin homology domain containing, family H (with 
MyTH4 domain) member 1  Plekhh1 2.11 
NM_133774 StAR-related lipid transfer (START) domain containing 4  Stard4 2.11 
NM_001146022 WD repeat and FYVE domain containing 4  Wdfy4 2.11 
NM_001008233 pleckstrin homology domain containing, family N member 1  Plekhn1 2.1 
NM_177775 extended synaptotagmin-like protein 3 Esyt3 2.07 
NM_026235 La ribonucleoprotein domain family, member 6 Larp6 2.07 
NM_019814 HIG1 domain family, member 1A  Higd1a 2.06 
NM_177185 ubinuclein 2  Ubn2 2.06 
NM_001256057 predicted gene 11570  Gm11570 2.05 
NM_172694 multiple EGF-like-domains 9 Megf9 2.05 
NM_177632 family with sequence similarity 43, member A  Fam43a 2.04 
NM_001146043 G elongation factor, mitochondrial 2,  transcript variant 2 Gfm2 2.04 
NM_027116 NTPase, KAP family P-loop domain containing 1  Nkpd1 2.04 
NM_028950 
NOL1/NOP2/Sun domain family member 6, transcript 
variant 2 Nsun6 2.04 
NM_001271727 tripartite motif-containing 2, transcript variant 3 Trim2 2.02 
NM_016714 nucleoporin 50  Nup50 2.01 
NM_001045483 
mitogen-activated protein kinase 1 interacting protein 1, 
transcript variant 1 Mapk1ip1 2 
    
 Protein folding   
NM_028430 peptidylprolyl isomerase (cyclophilin)-like 6  Ppil6 2.25 
NM_018808 DnaJ (Hsp40) homolog, subfamily B, member 1 Dnajb1 2.23 
    
 Proteolysis   
NM_013459 complement factor D (adipsin)  Cfd 11.31 
NM_177322 angiotensin II receptor, type 1a  Agtr1a 8.65 
NM_011414 secretory leukocyte peptidase inhibitor Slpi 7.4 
NM_008871 serine (or cysteine) peptidase inhibitor, clade E, member 1  Serpine1 6.57 
NM_001252569 
serine (or cysteine) peptidase inhibitor, clade A, member 
1A, transcript variant 2 Serpina1a 3.91 
NM_133753 ERBB receptor feedback inhibitor 1  Errfi1 3.83 
NM_001199940 serine (or cysteine) peptidase inhibitor, clade A, member 3I  Serpina3i 3.72 
NM_015790 icos ligand  Icosl 3.69 
NM_010511 interferon gamma receptor 1 Ifngr1 3.56 
NM_009247 
serine (or cysteine) peptidase inhibitor, clade A, member 
1E  Serpina1e 3.47 
NM_028660 kallikrein related-peptidase 9 Klk9 3.39 
NM_009245 
serine (or cysteine) peptidase inhibitor, clade A, member 
1C  Serpina1c 3.31 
NM_024406 fatty acid binding protein 4, adipocyte  Fabp4 3.12 
NM_009776 serine (or cysteine) peptidase inhibitor, clade G, member 1  Serping1 3.09 
NM_011113 plasminogen activator, urokinase receptor  Plaur 2.99 
NM_009543 ring finger protein 103  Rnf103 2.98 
NM_007796 
cytotoxic T lymphocyte-associated protein 2 alpha, 
transcript variant 1 Ctla2a 2.87 
NM_009246 
serine (or cysteine) peptidase inhibitor, clade A, member 
1D  Serpina1d 2.87 
NM_027997 serine (or cysteine) peptidase inhibitor, clade A, member 9 Serpina9 2.83 
NM_007781 colony stimulating factor 2 receptor, beta 2, low-affinity  Csf2rb2 2.79 
NM_178691 YOD1 OTU deubiquitinating enzyme 1 homologue Yod1 2.71 
NM_001025439 
calcium/calmodulin-dependent protein kinase II, delta, 
transcript variant 1 Camk2d 2.62 
NM_016845 proacrosin binding protein, transcript variant 1 Acrbp 2.61 
NM_026414 aspartic peptidase, retroviral-like 1 Asprv1 2.61 
NM_019932 platelet factor 4  Pf4 2.47 
NM_001039042 kallikrein related-peptidase 13  Klk13 2.42 
NM_007797 
cytotoxic T lymphocyte-associated protein 2 beta, transcript 
variant 1 Ctla2b 2.41 
NM_008906 cathepsin A , transcript variant 1 Ctsa 2.41 
NM_173749 
peptidase domain containing associated with muscle 
regeneration 1  Pamr1 2.4 
NM_001040106 AP2 associated kinase 1, transcript variant 1 Aak1 2.26 
NM_178730 transmembrane protease, serine 11f  Tmprss11f 2.23 
NM_028894 LON peptidase N-terminal domain and ring finger 3  Lonrf3 2.21 
NM_011177 kallikrein related-peptidase 6, transcript variant 1 Klk6 2.2 
NM_183284 serine peptidase inhibitor, Kazal type 2  Spink2 2.17 
NM_001081115 
non-specific cytotoxic cell receptor protein 1 homolog 
(zebrafish)  Nccrp1 2.13 
NM_052976 oligophrenin 1  Ophn1 2.12 
NM_178694 zyg-11 related, cell cycle regulator  Zer1 2.11 
NM_139147 Rab40b, member RAS oncogene family  Rab40b 2.06 
NM_007899 extracellular matrix protein 1, transcript variant 1 Ecm1 2.05 
NM_001001803 serine peptidase inhibitor, Kazal type 7 (putative)  Spink7 2.04 
    
 RNA processing   
NM_011756 zinc finger protein 36  Zfp36 4.91 
NM_007475 ribosomal protein, large, P0 Rplp0 2.95 
BC096413 ribosomal protein L37a Rpl37a 2.82 
NM_001114079 poly(A) binding protein, cytoplasmic 1-like  Pabpc1l 2.8 
NM_133819 protein phosphatase 1, regulatory (inhibitor) subunit 15b  Ppp1r15b 2.79 
NM_009095 ribosomal protein S5  Rps5 2.62 
NM_033541 2'-5' oligoadenylate synthetase 1C  Oas1c 2.43 
NM_025963 ribosomal protein S10  Rps10 2.42 
NM_026020 ribosomal protein, large P2  Rplp2 2.22 
NM_016680 
CLK4-associating serine/arginine rich protein, transcript 
variant L Clasrp 2.14 
NM_053255 elaC homolog 1 Elac1 2.1 
NM_025919 ribosomal protein L11  Rpl11 2.1 
NM_175937 
cytoplasmic polyadenylation element binding protein 2 , 
transcript variant 1 Cpeb2 2.09 
NM_175529 leukocyte receptor cluster (LRC) member 9 Leng9 2.07 
NM_011287 ribosomal protein L10A  Rpl10a 2.03 
NM_001024837 
adenosine deaminase, RNA-specific, B1, transcript variant 
2 Adarb1 2.02 
    
 Signalling   
NM_011314 serum amyloid A 2  Saa2 40.51 
NM_008176 chemokine (C-X-C motif) ligand 1 Cxcl1 23.24 
NM_009117 serum amyloid A 1  Saa1 12.21 
NM_011333 chemokine (C-C motif) ligand 2  Ccl2 9.04 
NM_008361 interleukin 1 beta  Il1b 8.5 
NM_009627 adrenomedullin Adm 7.04 
NM_007707 suppressor of cytokine signaling 3  Socs3 4.9 
NM_007913 early growth response 1 Egr1 4.62 
NM_015811 regulator of G-protein signaling 1  Rgs1 4.39 
NM_011338 chemokine (C-C motif) ligand 9 Ccl9 4.29 
NM_177868 
forkhead-associated (FHA) phosphopeptide binding 
domain 1 Fhad1 3.93 
NM_013652 chemokine (C-C motif) ligand 4 Ccl4 3.8 
NM_015776 microfibrillar associated protein 5  Mfap5 3.58 
NM_026577 ADP-ribosylation factor-like 13B  Arl13b 3.55 
NM_029083 DNA-damage-inducible transcript 4 Ddit4 3.51 
NM_008344 insulin-like growth factor binding protein 6  Igfbp6 3.38 
NM_011817 growth arrest and DNA-damage-inducible 45 gamma  Gadd45g 3.37 
NM_009615 a disintegrin and metallopeptidase domain 17 Adam17 3.33 
NM_009061 regulator of G-protein signaling 2  Rgs2 3.28 
NM_017466 chemokine (C-C motif) receptor-like 2 Ccrl2 3.27 
NM_020622 family with sequence similarity 3, member B  Fam3b 3.19 
NM_009841 CD14 antigen  Cd14 3.17 
NM_146491 olfactory receptor 1410  Olfr1410 3.14 
NM_011905 toll-like receptor 2  Tlr2 3.14 
NM_177137 
guanine nucleotide binding protein, alpha stimulating, 
olfactory type, transcript variant 2 Gnal 3.07 
NM_145857 nucleotide-binding oligomerization domain containing 2  Nod2 2.99 
NM_172718 small G protein signaling modulator 1, transcript variant 1 Sgsm1 2.99 
NM_009017 retinoic acid early transcript beta  Raet1b 2.95 
NM_023463 lymphocyte antigen 6 complex, locus G6C Ly6g6c 2.84 
NM_001163262 c-Maf inducing protein, transcript variant 1 Cmip 2.8 
NM_027106 arginine vasopressin-induced 1 Avpi1 2.77 
NM_010276 GTP binding protein Gem 2.76 
NM_008855 protein kinase C, beta  Prkcb 2.62 
NM_021274 chemokine (C-X-C motif) ligand 10 Cxcl10 2.61 
NM_001163634 
wingless-related MMTV integration site 7B, transcript 
variant 2 Wnt7b 2.59 
NM_178256 RALBP1 associated Eps domain containing protein 2  Reps2 2.58 
NM_007706 suppressor of cytokine signaling 2, transcript variant 1 Socs2 2.57 
NM_013693 tumor necrosis factor  Tnf 2.52 
NM_025540 sarcolipin  Sln 2.46 
NM_001081155 Rap1 GTPase-activating protein , transcript variant 1 Rap1gap 2.45 
NM_009184 PTK6 protein tyrosine kinase 6  Ptk6 2.44 
NM_010592 Jun proto-oncogene related gene d Jund 2.43 
NM_011058 
platelet derived growth factor receptor, alpha polypeptide , 
transcript variant 1 Pdgfra 2.42 
NM_010831 salt inducible kinase 1 Sik1 2.39 
NM_008773 purinergic receptor P2Y, G-protein coupled 2  P2ry2 2.37 
NM_025404 ADP-ribosylation factor-like 4D  Arl4d 2.36 
NM_022019 dual specificity phosphatase 10  Dusp10 2.36 
NM_008343 insulin-like growth factor binding protein 3 Igfbp3 2.33 
NM_001130409 PTK2 protein tyrosine kinase 2, transcript variant 2 Ptk2 2.32 
NM_001081212 insulin receptor substrate 2 Irs2 2.31 
NM_178111 
transformation related protein 53 inducible nuclear protein 
2  Trp53inp2 2.3 
NM_178258 interleukin 22 receptor, alpha 2  Il22ra2 2.28 
NM_013584 leukemia inhibitory factor receptor, transcript variant 1 Lifr 2.28 
NM_198703 WNK lysine deficient protein kinase 1, transcript variant 1 Wnk1 2.28 
NM_001035533 A kinase (PRKA) anchor protein 2, transcript variant 1 Akap2 2.25 
NM_018883 
calcium/calmodulin-dependent protein kinase kinase 1, 
alpha Camkk1 2.24 
NM_021306 endothelin converting enzyme-like 1 Ecel1 2.24 
NM_010559 interleukin 6 receptor, alpha Il6ra 2.22 
NM_175445 Ras association (RalGDS/AF-6) domain family member 2  Rassf2 2.22 
NM_011530 
transporter 2, ATP-binding cassette, sub-family B 
(MDR/TAP)  Tap2 2.16 
NM_139307 vasorin  Vasn 2.16 
NM_010950 numb-like  Numbl 2.15 
NM_133924 sorting nexin family member 21  Snx21 2.12 
NM_001025250 vascular endothelial growth factor A, transcript variant 1 Vegfa 2.1 
NM_007557 bone morphogenetic protein 7 Bmp7 2.09 
NM_001002842 
PML-RAR alpha-regulated adaptor molecule 1 (Pram1), 
transcript variant 1 Pram1 2.09 
BC122879 nebulette Nebl 2.05 
NM_080843 suppressor of cytokine signaling 4  Socs4 2.02 
NM_146322 olfactory receptor 187  Olfr187 2.01 
NM_178710 salt inducible kinase 2  Sik2 2.01 
NM_001081412 breakpoint cluster region Bcr 2 
    
 Transcription   
NM_001077364 TSC22 domain family, member 3, transcript variant 1 Tsc22d3 13.68 
NM_007498 activating transcription factor 3 Atf3 7.41 
NM_008036 FBJ osteosarcoma oncogene B  Fosb 7.34 
NM_010444 nuclear receptor subfamily 4, group A, member 1  Nr4a1 7.12 
NM_010234 FBJ osteosarcoma oncogene  Fos 6.58 
NM_010828 
Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2  Cited2 6.21 
NM_007679 CCAAT/enhancer binding protein (C/EBP), delta  Cebpd 5.67 
NM_153287 cysteine-serine-rich nuclear protein 1 Csrnp1 4.92 
NM_001033324 zinc finger and BTB domain containing 16  Zbtb16 4.28 
NM_010591 Jun oncogene  Jun 4.23 
NM_016868 
hypoxia inducible factor 3, alpha subunit , transcript variant 
2 Hif3a 4.01 
NM_007914 ets homologous factor  Ehf 3.86 
NM_008390 interferon regulatory factor 1, transcript variant 1 Irf1 3.81 
NM_001113333 cryptochrome 2 (photolyase-like) , transcript variant 2 Cry2 3.67 
NM_010638 Kruppel-like factor 9 Klf9 3.46 
NM_010907 
nuclear factor of kappa light polypeptide gene enhancer in 
B cells inhibitor, alpha  Nfkbia 3.39 
NM_021897 
transformation related protein 53 inducible nuclear protein 
1, transcript variant 1 Trp53inp1 3.39 
NM_010755 
v-maf musculoaponeurotic fibrosarcoma oncogene family, 
protein F Maff 3.33 
NM_008452 Kruppel-like factor 2 Klf2 3.14 
NM_027477 zinc finger protein 398 , transcript variant 1 Zfp398 3.06 
NM_013874 D4, zinc and double PHD fingers family 1 Dpf1 3 
NM_010235 fos-like antigen 1  Fosl1 2.99 
NM_009821 runt related transcription factor 1, transcript variant 4 Runx1 2.97 
NM_017373 nuclear factor, interleukin 3, regulated Nfil3 2.94 
NM_030612 
nuclear factor of kappa light polypeptide gene enhancer in 
B cells inhibitor, zeta , transcript variant 1 Nfkbiz 2.88 
NM_010056 distal-less homeobox 5, transcript variant 1 Dlx5 2.79 
NM_009565 zinc finger and BTB domain containing 7B Zbtb7b 2.71 
NM_011276 ring finger protein, LIM domain interacting  Rlim 2.7 
NM_010499 immediate early response 2 Ier2 2.63 
NM_023755 transcription factor CP2-like 1  Tfcp2l1 2.58 
NM_027947 
zinc finger and BTB domain containing 43, transcript 
variant 1 Zbtb43 2.57 
NM_011498 basic helix-loop-helix family, member e40 Bhlhe40 2.48 
NM_009637 AE binding protein 2, transcript variant 3 Aebp2 2.47 
NM_153599 cyclin-dependent kinase 8  Cdk8 2.47 
NM_020610 nuclear receptor interacting protein 3  Nrip3 2.46 
NM_023184 Kruppel-like factor 15 Klf15 2.42 
NM_183208 zinc finger, MIZ-type containing 1  Zmiz1 2.4 
NM_013519 forkhead box C2 Foxc2 2.39 
NM_001029929 zinc finger, MYND-type containing 15  Zmynd15 2.38 
NM_010137 endothelial PAS domain protein 1 Epas1 2.37 
NM_021397 zinc finger and BTB domain containing 32 Zbtb32 2.37 
NM_027264 zinc finger protein 715 Zfp715 2.34 
NM_011803 Kruppel-like factor 6  Klf6 2.3 
NM_175606 HOP homeobox, transcript variant 1 Hopx 2.29 
NM_011753 zinc finger protein 26 Zfp26 2.29 
NM_177993 
high mobility group box transcription factor 1, transcript 
variant 2 Hbp1 2.25 
NM_011066 period circadian clock 2  Per2 2.22 
NM_001100460 zinc finger and BTB domain containing 42 Zbtb42 2.22 
NM_009744 B cell leukemia/lymphoma 6  Bcl6 2.19 
NM_008554 achaete-scute complex homolog 2 (Drosophila) Ascl2 2.15 
NM_001025577 
avian musculoaponeurotic fibrosarcoma (v-maf) AS42 
oncogene homolog Maf 2.15 
NM_177660 zinc finger and BTB domain containing 10 Zbtb10 2.15 
NM_009884 CCAAT/enhancer binding protein (C/EBP), gamma Cebpg 2.06 
NM_010658 
v-maf musculoaponeurotic fibrosarcoma oncogene family, 
protein B  Mafb 2.04 
NM_008270 homeobox B9 Hoxb9 2.03 
NM_001009935 thioredoxin interacting protein, transcript variant 1 Txnip 2.03 
NM_177790 zinc finger protein 385C Zfp385c 2.01 
NM_001029838 Pbx/knotted 1 homeobox 2 , transcript variant 2 Pknox2 2.01 
NM_172643 zinc finger and BTB domain containing 41 homolog Zbtb41 2.01 
NM_031391 general transcription factor II A, 1, transcript variant 1 Gtf2a1 2 
    
 Transport   
NM_008432 potassium channel, subfamily U, member 1  Kcnu1 2.48 
NM_020506 exportin 4  Xpo4 2.09 
NM_029491 trafficking protein particle complex 8, transcript variant 2 Trappc8 2.04 
NM_011324 sodium channel, nonvoltage-gated 1 alpha  Scnn1a 2.03 
NM_172476 transmembrane channel-like gene family 7  Tmc7 2.01 
 
*genes validated by qPCR 
